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A b tract 
ndr gen d privation th rap y ( T) i a c 1nm n meth d f tr atm nt D r pr tate cancer. 
There ar a ari ty of ide eft ct a ciated with it u e that an nega ti ely impa t h alth and 
quality of lit y t a ignificant gap i t in th lit rature ar und mpr h n ive creenmg 
rec 1nmendation . a re ult, thi pr j ect k t an wer the qu ti n: r N ur Practitioner 
(NP ) practi cing in a primary care tting, what creening i requi r d t id entify id eft c t in 
men with pro tate cancer receiving T . ligibility criteri a fi r thi literature review included 
data related to DT and men with pr tate cancer, with no limitati n t ag r tage of di ea e. 
The majority of the participant in the primary tudie included at least one tudy group 
receiving ADT in the primary care etting. Thi review pre ented findin g ba ed on th phy ical 
cognitive and p ychological ide ffect f ADT, fi !lowed by a de cription of clinical practi ce 
guidelines, cl inical review and editori al in order to highlight the gap in creening 
reco1nmendations. Through this proce , recommendation fo r the creening of each individual 
ide effect were developed. It was detem1ined that patient should undergo fo llow-up within 3 
months of ADT initi ati on, fo llowed by every 3-6 months. Limitat ions of thi s project incl ude a 
scarcity of studies on pecific side effects. Implica tion for practice include patient and primary 
care provider (P P) education as well as the development of comprehen ive guideli ne . 
Moreover, further research is required fo r newly defined side effect . It i through appropriate 
screening that ADT related side effect are id entifi ed and treated, thu limiting their impact on 
health and quality of life. 
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Glo ary 
Androgen are mal h rm n primarily te t terone and dih ydr t t r ne ( m n can ancer 
ciety 2014 ). 
Andropau e g nerally ccur in m n betwe nth ag f 45 and 55 in which te t terone level 
fall leading to redu e xual dri and vig ur (andr pau e, 20 15) . ltem atively called mal e 
menopau (andr pau , 20 15) . 
Anorgasmia i the inability to achieve rga m (lntemati nal ociety [! r exual M dicine, 
2015). 
Anti-a ndrogen area l o kn wn a andr gen bi ynthe i . They work by inhibiting adrenal and 
intra-tumour production of te to terone. amp] in Ketoconaz le and yr t r on (Locke & 
lliot, 20 15). 
Asthenia i characterized by g n rali zed weakne and can al o include phy ical and mental 
fatigue (Bruera & MacDonald, 19 ). 
Brachytherapy is a typ of cancer treatment that refe rs to the placem nt of radioactive 'seed ' 
into the body, either inside or next to a tumour. The eeds deli ver radiation to th cancerou 
tumor while minimizing the unounding ti s ues expo ure to radiation. Thi method of radiation 
therapy i commonly u eel for pro tate cancer, which is call ed Tran perineal Implantati on of the 
Prostate (TPIP) . During TPIP radioactive seed are inset1ed into the pro tate under general 
anesthesia (Briti h Columbia Cancer Agency [BC ], 20 14a) . 
Cryotherapy is a form of prostate cancer treatment that freezes and de troy prostate cancer 
cell s (National Cancer In titute [NCI], 20 15) . 
Erectil e dysfun ction is defined as the persistent inability to achieve or maintain an erection 
(Buttaro, Trybulski, Polgar Bailey, & and berg- ook, 20 13 ). 
External beam radiation is the use of high energy ray to kill or hrink malignant tumour cell 
(B A, 20 14a). 
FRAX is a fracture ri k a essment tool developed from th e World Health rganization . Th 
tool incorporates individual patient ri k factors in combination with bone mineral den ity re ult 
and gives a 10 year probability of fracture (World Health rganization llaborating entre for 
Metabolic Bone Disea e, n.d .). 
Gynecomastia i deGned a the benign enlargement of the male brea t and i the rc. ult of 
proliferation of ductular element of the brea t (Buttaro et al., 201 ). 
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Gonadotropin relea in g hormone (GnRH) i a ynth 
relea ing h rm n ag ni t (LHRH) with nti all y th 
20 12a). 
tic anal g f Jut iniz ing h rm n 
am e m chani m f ac ti on (B 
Hemoglobin i a lab rat ry te t that d t rmine the t ta l am unt f hem gl bin in the b1 d. 
H m gl bin it lf a t a a v hi 1 [! r th tran p rtati n f ygen and arbon di x id 
through ut th b dy. The te t i an imp rtant part f the c mplete bl d cell count ( B ) and 
can be helpfu l in va luating [! r an mia (Pagana & Pagana, 201 ). 
Hemoglobin Al or gly ylat d h m gl bin i a mea urem ent u d c mm n ly in diabetic 
patient fi r di agno i and t m onit r r p n e t trea tment (Pagana & Pagana 20 l ). The value 
refl ect an average bl d glue e lev I in the bl d ver a 100 t 120 day pan (Paga na & 
Pagana 20 13). 
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High density lipoprotein (HDL) i o ft n r fe rred t a 'g od cho le ter I' a it is re p n ib le fo r 
co li cting cho l t ro l from th b dy' ti u and end oth e lium and returnin g itt th e li ve r. 
Removal of chole terol from the ti ue and endothelium provide prot c ti n aga in t heart 
di ea e (Pagana & Pagana 20 13) . 
Hypogonadism occurs when ex gland , uch a the te tes in m en and ovari e m women 
produce reduced or ab ent am ount of ex hormone (M aJiel, 20 1 2) . 
Impotence refer to the inability to achieve or maintain an erection ( ilverberg, 20 15). 
Insulin resistance i the "de reased en iti v ity of ti s ue to g luco e uptake w ith norm al 
concentrations of in ulin'' (Buttaro et al. , 20 13, p . 1 062). 
Libido is ones sexual drive or in tinct (l ibido, 20 15) . 
Low density lipoprotein (LDL) i part of the lipid profi le. LDL catTies cholesterol from the 
liver to di ffere nt ce ll s in the body. LDL is often re~ rr d to as 'bad chole tero l' (Paga na & 
Pagana, 20 13). 
Luteinizing hormone releasing hormone agonist (LHRH) are medica ti on u ed for pro tate 
cancer. Mechanism of action i the over timulation of the hypothalamu -pitu itary-adrenal te te. 
axis which stops the production of te tosterone. xampl e include serelin and Leuprolide 
(Locke & lliot, 20 15). 
Mean corpuscular volume (M V) refers to the volume or ize of a ingl red blood cell. Its 
measurement i comm only used to help classify anemi a (Pagana & Pagana, 2013 ) . 
Metasta i i the term used to de crib when cancer cell pread from it · original (primar ) 
location to another area in the body. When this oc ur the ancer c ntinuc to grow in it new 
loca tion ( anad ian ancer o icty, 20 14a) . 
Neo-adjuvant re£ r t cancer treatment that i giv n prior to the m ain tr atment pre cribed 
(N I, n .d.). 
Orchiectomy i th urgi al r moval of the te tiel ( anadian ancer ciety 20 14a). 
Osteopenia refer to abnonnal (low) bon den ity, but n t as low a b ne density in the 
o teop rotic rang (Karaguz 1 & H lick, 20 1 0). 
Osteoporosis i a di ea e in which bone b come more fragile with increa ed susc ptibility for 
fractur (Buttaro et al. , 20 1 ). 
Pro tate pecific Antigen (PSA) i an enzyme re l a d by the pro tate gland. Levels can be 
elevated related to both benign and malignant conditi n . A normal P A level i under 4 ng/mL. 
Level can be mea ured with a erum laboratory te t (Buttaro et al. , 20 13). 
Psychometrician i a p ychologi t who i skill ed in administering and interpreting 
psychological test (P ychim trician, 20 15). 
Quali ty of life definiti ons can vary widely. The World Health Organiza ti on (1997) defin es 
quality of life as an " indi vidual' s percepti on of th ir pos iti on in I ife in the context of the cultur 
and value systems in which they live and in relation to their goal , exp ctations, standard , and 
concerns. It is a broad rangin g concept affected in a compl ex way by the perso n's phy ica l 
health, psychological state, level of independence, social relati on hip , per onal beliefs and their 
relation hip to salient features of their env ironm ent" (p. 1) . 
Radical prostatectomy is a surgical procedure done for locali zed prostate cancer (BC A, 
20 14b ). The surgery involves removing and sampling pelvic lymph nodes, and if negative for 
malignancy, the rem oval of the prostate gland and seminal vesicle (BCCA, 20 14b ). Conlffion 
side effects include incontinence and erectile dysfunction (BCCA, 20 14b ). 
Testosterone is a honnone which is primarily produced in the testes, with small amounts 
produced in the ovaries and adrenal cm1ex. This hormone is primari ly responsible for the 
development of m ale secondary sexual characteristics (Testosterone, 20 15). 
Triacylglycerol also refers to triglycerides, which are naturall y occmTing fatty acid and 
glycerol found in oil and fats (Triacylglycerol 20 15). 
Very low density lipop rotein (VLDL) is another laboratory component of the lipid profile. 
VLDL canie triacylglyceroJ from the liver to adipose ti sue in the body (Pagana & Pagana, 
20 13) . 
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Introduction 
The diagn f anc r can b a life-al t ring event. th cane rand it treatment can 
impact phy ical c gnitive and p ych gical function all of which can influenc elf- teem; 
intimate and ocial r lation hip ; and o erall health and quality f liD 0 Pro tat cancer i th 
econd mo t comm nly diagn d cancer in men w rldwide ( adro & arzotto, 2011 )0 
Con equently with uch ignifi ant pre al nee rat the likelih d that primary care provider 
(P P ), uch a Nur Practiti n r ( P ) will be inv lved with the diagn i and managem nt 
of this di ea e is ubstantial. Moreover, ex ten ive progre in pr tate cancer trea tm nt have 
extend d life xp ctancy, meaning pati ent are living longer with the di ea e and obtaining care 
and treatment by P P in the conununitie in which they live (In titute of Medicine, 2008)0 
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aturally, the level of interacti n between P P and patient depends on the method of 
treatment and ymptomology related to b th cancer and treatm ent 0 For exampl e, androgen 
deprivation therapy (ADT), which i a form of honnone therapy, i commonly pre cribed by 
specialists but administered and managed by PCPso ADT is the most co1nmon method of 
treatment for prostate cancer, with estimations that at lea t 50% of patients with pro tate cancer 
will be treated with ADT at orne point in their illness (Mohile, Mustian, Bylow, Hall, & Dale, 
2009; Tadros & Garzotto, 20 1 1 )0 ADT reduces te to terone to ca trate levels that inhibits or 
slow the growth of hormone dependent cancer c 11 (Mazzola & Mulhall, 2012)0 Androgen 
deprivation is achieved through suppre ing the production of androgen by the te te , which 
produce 90-95% of the body' total androgen, or by blocking the effect of androgen at androgen 
receptor (Mazzola & Mulhall, 20 12)0 
With the reduction of te to terone comes a vari ty of arly and lat ide efT ct , a well 
a an increa ed ri k for th r health condition such a cardio a ular di case, diabet s, 
te p ro i and functi nal d line. Furthermore, the literature ha dem n trated that verall 
tho e with ancer die f non-can r r lated cau at a much hi gher rat than the general public 
(Br wn tal. , 200 a c ited in tull tal. , 2007). inally, th e trea t d with DT dem n trat 
ignifi cantly wor quality f life with chang t both m ntal and em ti nal well-b ing ( ary, 
ingla, owan, anoll, perberg, 20 14; van ndel & Kurth, 200 ). Thi highli ght the 
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nece ity t acknowledge th 1 ng t nn health and p ychol gical cqu lae a ciat d with ADT 
and the ub equent need t con ider creening and identificati n of id e effect in rder t 
commence appropriate treatment. 
Primary care provider , uch a NP , are oft n the fir t and m t frequ nt p int of contact 
for patient when acce ing car with c ntinu d re ponsibility ~ r providing pati ent care for a 
variety of health probl em (American cademy f Family Phy ician , 20 15; Heal th F rc 
ntario, 20 13). Thi ongo ing e tabli hed relation hip between patient and P P i pivo tal for 
the identification of ADT related side effect to en ure trea tmen t i provided to maximize hea lth 
and quality of life during thi treatment. However, an important con ideration for providing thi 
complex peciality care i availability and knowledge of up to date re ources and t ol . ntil 
recently, the focu of prostate cancer re earch ha been largely focu ed on treatment and 
achieving long-term surviva l. A a result, the literature illustrate an ab undance of data regarding 
the effectiveness of ADT and its as ociated side effect , however pecific recommendation or 
practice guidelines for the eva lu ation of ide effect are par e (Mclnto h et al., 2009) . imilarl , 
alth ugh ri ks of developing additional health condition related to DT are docum ntcd in the 
literature, guidelines related to creening for the e health conditi n are not w II defined or 
c mprehcn ive. n equently, P P have little evid n e to guide care with regard · tom 'thod · 
and frequ ncy fa e mcnt [I r tho c rccci ing D . Without c mprchcnsi\ e guid ~ Jin ' S r 'a dil ~ 
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available, P P will hav limited awar ne f the ub tantial impact f DT on health related 
quality of life and appropriat tr atm nt of ide effect cannot be adequ ately pr vid d . 
Furthermore, the literatur ha identified gap in are with regard to ~ 11 w up and screening for 
ide effect in tho e recei mg DT d mon trating a furth r need. 
The obj ctive of thi integrati ve literature review i t an wer the following que tion : or 
NP practicing in a primary care etting, what creening i requir d t identify ide effect in 
men with pro tate cancer rec i ing DT. The rev iew will begin by de cribing pr tate cancer in 
primary care, the role of the P a a P P, pro tat cancer incidence a well a pro tate anatomy 
and pathophy iology. Pro tate cancer treatment , DT and it ide ffect will then be di scu sed . 
Next, the literature earch proce will be de cribed. inding fro m the integrati v review will 
then be pre ented followed by implicati n and reconun endati on for prim ary care practi ce, 
education and re earch. 
Pro tate ancer in Primary are 
hapter ne 
Background and ontext 
Primary care i central to the di agn i and m anagem ent f cancer ( utrunert n, 2000 a 
cit d in Allgar & eil , 200 5). Primary are ften re fer t a pati nt' fir t conta t for medi cal 
care, in which P P , uch a n ral Pra titi ner and P , a um re p n ibi lity [! r 
continuou , comprehen iv and c - rdinat d care ( tarfield , 1994 as cited in llgar & eil 
2005). Primary car inc lud health prom tion, di ea e preventi n, health maintenance, 
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coun eling, patient ducation, di agno i and treatm nt of illne a well a facilitating acce s to 
specialty care (American cademy of Family Phy ic ian , 20 15). s a re ult, P Ps provide a 
focal point for continuous health care and thu are generally invol ved in care prior to diagnosi 
and have a well-e tablished relation hip and role in ongoing care (Department of Health, 2000 a 
cited in Allgar & Neil, 2005 ). Although traditionally health care management of tho eon acti v 
treatment for cancer ha been limited to speciali st and outpati ent oncology clini c , care for tho e 
receiving hormonal treatment regimens uch as ADT has now hifted to the PCP . Thus, P Ps 
have increasing respon ibility for greater a pect of cancer care, uch as fo ll ow up , a se ment 
and managem ent of side effects and co-morbiditi e , and for ambulatory treatment in the 
community (Al lgar & N eal, 2005). Additi ona ll y, with ADT' demon trated improve ment 111 
longevity of life, pati ents are living longer with per i tent di ea e that crea te additi onal 
con iderations for P Ps in regards to incorporating appropri ate crcening for both di ea e and 
trea tment related side effects. 
The Role of the Nur e Practitionea· 
Nur practiti ner (N P ) are autonomou h alth care providers . Ps ha e und rgraduate 
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educati nand exp ri ence in nur ing, with additi nal Ma ter or PhD level educa ti n from aero 
h alth di ciplin , including m di ine. P' bring t g ther th medi ca l knowledg required of a 
P P, uch a th ability t diagn e di ea e and conditi n , rd r diagn tic te t and pre crib 
and manage medication and treatment , with the value and ki ll of the nur ing pr fe i n 
( anadian ur e A ociation, 20 11 ). Mor ver, P' pr vide direct pati ent are, addressing 
health promotion, illne s preventi n, diagn i and treatm ent f acut and chr nic illne within 
the cope of a holi tic nur ing per pective ( anadi an Regi tercd ur e of Briti h olumbia 
[CRNB ], 20 15a). ince incepti n f the ro le in anada in th e earl y 1960' , the va lue of the 
NP' role in the anadian h alth car y t m ha been identified bynum r u tudie , 
demon trating "timely acce to indi viduali ed, high qua lity, co t effective care" ( anadian 
Nur e A ociati n, 20 I I , para . I 0). Although P' are current ly restricted in pre cribin g ADT, 
the NP's role as a PCP erve a a continu ou foca l point for managing patients throughout the 
cancer trajectory. Thus, throughout cancer treatment patient will continue to access care in 
which NP's can provide competent assessments, upport, educa tion and counselling with regard 
to diagnoses, management and therapeutic interventions. Additionally, NP's can perform any 
appropriate screening and diagnostic invc tigations required for cancer and it treatments u ing 
standardized tools, laboratory and diagnostic imaging (CRNB , 20 15b ). 
Prostate Cancer Incidence 
In an ada, prostate cancer i the most common type of cancer diagno ed in men, 
accounting for 24% of all new cancer diagno e in men in 2014 ( anadian ancer ociety, 
20 14a). Similarly, prostate cancer is the mo t frequ ntly diagno ed cancer in men in Briti h 
lumbia, with approximately 3600 men diagnos d in 2014, and over 25 000 men tlu·oughout 
anada in 20 ll ( anadian an er ciety, 20 l4b; Venkate waran, Margel, Yap, H rsc , Yip, · 
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Fie hner, 20 12) . De pi te the high incidence, du t th natur f th di ea a well a the 
developm nt of ucc ssfu l treatment modalitie motiality rates are relatively low . Fiv year 
relative urvival rate remain high at 96%, with an verall death rate f 17 men for every 
100,000 people ( anadian anc r oci ty, 20 14a). The averag ag f diagn i i 79 years old , 
with ov r 70% of case in men over the ag of 65 year old (Mohile et al. 2009) . 
Anatomy and Pathophy iology 
The pro tate i a mall gland D und in men pati of both the male urinary and 
reproductive ystem ( anadian ancer ociety, n .da). The gland unound s the base of the 
bladder a well as a portion of the urethra and its in front of the rectum ( anadian Cancer 
Society, n.da; Prostate Cancer Foundation, n.d.) . Prostate ize varie in men, but on average the 
pro tate is the ize of a walnut (Pro tate Cancer Foundation, n .d.). Sunounding the pro tate are 
the seminal vesicles, which are small glands involved in the ecretion of semen, and nerve that 
control erectile function run alongside and attach to the prostate gland (Prostate Cancer 
Foundation, n.d.). Although not essential for life, the prostate gland pl ays an e entia! role in 
reproduction through the production of protein and mineral rich fluid that nourishes and 
maintains sperm (Canadian Cancer Society, n.da ). Further, due to the prostate sunounding the 
urethra, muscle cells in the prostate gland also play a role in controlling the flow of mi ne und r 
invo luntary nervous system control (Canadian ancer Society, n .da.) . The gland it elf i divided 
into anatomic regions, repmied as the peripheral, transitional and central zones (Pro tate ancer 
Foundation, n.d.). The majority of prostate cancer tumors develop in the peripheral zone, which 
is the largest area of the prostate (Canadian ancer Society, n.da) . This area is close t to the 
rectum and can ea il y be felt during a digital rec tal examination ( ana dian ancer ociet , n.da ). 
he transitional zone i the middle of th pro tate gland and can enl arge with age, while the 
central zone i fa11he t from the rectum and thu cannot bee amin d via digital rectal 
examination ( anadian Cancer ociety, n.da). 
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Androgen uch a te to terone and dihydrote to terone (DHT) play a crucial role in the 
normal development and biology of the pro tate gland ( irling, Whitaker, Mills, & Neal, 2007) . 
However, the e potent mal hormone areal o required fo r the development of pro tate cancer 
which is often referred to a a hormone dependent cancer ( irling et al. , 2007) . These androgens 
exe11 their deva tating effect by binding to androgen receptor (AR) in the cytopla m of the cell 
that allow the AR compl exe to enter the ce ll ' nucleus via nucl ar translocation ( irling et al. , 
2007) . Once in the nucleus, the AR complexes bind to specific DNA equences known a 
androgen response elements that promote growth of androgen respon ive genes (G irling et al. , 
2007) . These gene are re ponsible for many different cellular event , including increa e growth, 
survival and the expression of prostate specific antigen (PSA) (G irling et al. , 2007). It i becau e 
of this process that treatment fo r prostate cancer is often aimed at targeting the androgen 
receptors by reducing androgens levels or by inhibiting androgen receptor activation (Girl ing et 
al. , 2007) which will be discussed further below . 
Prostate-specific antigen (PSA) is a protein produced by the cell in the prostate gland 
(NCI, 20 12) . It is cmrunonly found in semen with small amounts found in the blood of healthy 
men ( anadian Cancer Society, n.db ). Mea uring PSA levels in the blood wa originall y 
approved to monitor for prostate cancer disease progression in those diagnosed with pro tate 
cancer, however with time it was recommended for use in conjunction with a digital rectal 
examination to screen for prostate cancer (NC I, 20 12) . Thi te t continue to be u ed as a ' tum or 
marker' to mon itor pro tate cancer re ponse to treatment and to monitor for progre ion or 
recurrenc f di ease ( anadian ancer ciety, n.db ). uch, change to P le el in the 
blood, uch a an increa e in P A during activ treatment or following treatment can indicate 
poor re pon e or recurrence ( anadian ancer ociety, n.db) . Whil a decrea e in P A level 
often indicate re pon e to treatment ( anadian ancer ociety, n.db ). 
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Until recently, creening for prostate cancer via a P A test was recommended for all men 
over the age of 50, how vera more ha been learned about th t t, recommendations are 
changing (N I, 2012). Test re ults are not definitive. levated te t result (>4 nghnL) do not 
indicate prostate cancer, as other benign conditi n can cause PSA elevations such as 
inflammation of the prostate (pro tatiti ) or enlargement of the prostate (benign prostatic 
hyperplasia) (NCI, 2012). Moreover, activitie uch as recent sexual intercourse, digital rectal 
examination or prostate biopsy can temporarily increase P A readings (Canadian Cancer 
Society, n.db ). PSA testing has also been associated with false positives, meaning the results 
suggest cancer though no cancer is present as well as false negatives, meaning the test fails to 
identify cancer (Canadian Cancer Society, n.db) . It is fm1her identified that PSA testing has led 
to the over diagnosis of prostate cancer, as testing may find cancer that poses no se1ious risk to a 
man's health , leading to unnecessary testing and treatment (Canadian Cancer Society, n.db) . 
Consequently, the majority of medical organizations and guidelines suggest patients are 
informed of the potential benefits and hanns of screening in combination with assessing per onal 
risk factors for developing prostate cancer (Canadian Cancer Society, n.db; NCI, 20 12). 
Prostate Cancer Treatments 
Androgen deprivation therapy (ADT) is the most widely used treatment modality for 
prostate cancer, most frequently used in tho e with metastatic or with high risk di ease 
( anadian ancer Society, 2014a; Mohile et al., 2009) . It is estimated that at least 50% of tho e 
diagnosed with prostate cancer will receive thi method of treatment at some point in their 
di ea e (Tadr & arz tt , 2011). It can be giv n a a ingle tr atment m dality r m 
combinati n with radiati nth rapy, either pri r t radiati n (n -adjuvant) or after radiati n 
therapy ( anadian ancer ci ty, 20 14a) . th r m thod f tr atment £1 r pro tat cane r 
in lude urge1-y uch a a radical pr tatect my r tran ur tlu·al re ecti n f th pro tate, active 
urveillanc (phy ical a e ment and P A te ting very to 6 month ), radiation, and 
chemotherapy ( anadian ancer ciety, 20 14a). 
Androgen Deprivation Therapy 
The clinical eU ct of uppr ing te t ter n I vel (androgen deprivati n) in tho 
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with advanced pro tate can er wa fir t identified by Huggin and Hodge in 1941 (Perlmutter & 
Lepor, 2007). Androgen deprivation wa found to be related t either urgical ca tration or 
through uppre ing the production of luteinizing hormone relea ing honnone (LHRH) by the 
hypothalamu u ing diethyl tilbe trol (D ) (Perlmutter & Lepor, 2007). ince that time 
hormonal suppre ion has been a widely accepted fonn of managing advanced pro tate cancer 
(Perlmutter & Lepor, 2007). DES wa eventually identified to be associated with signifi cant 
cardiova cular ri sks (Perlmutter & Lepor, 2007), o in 1971 new form of hormone uppre sion 
were developed through the manipulation of th ixth amino acid of gonadotropin relea ing 
hormone (LHRH), resulting in a potent LHRH agoni t called Leuprolide (Perlmutter & Lepor, 
2007) . Leuprolide was studi ed and accepted to be equally equiva lent in effi cacy to D with l s 
risk of cardiovascular toxicity (Perlmutter & Lepor, 2007) . Over the next everal decade everal 
other fonn ofLHRH agonist were developed and are currentl y in use today uch a go erelin 
and triptorelin (Perlmutter & Lepor, 2007) . urrentl y, there are four phan11acological ' Ia s of 
mcdicati ns used for androgen depriva tion: luteinizing honnone rclea ing honn ne agonists 
( HRH), nRH antagonist , anti -androgen and YP 17 inhibitor . LHRH agonist ' are cuiTentl 
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the pr [I rred mean f andr gen deprivati n m pra tic (HatTi Mo tagheJ N 1 n, & 
Montgomery, 2009) . The include Leuprolid , o er lin and Bu relin, which are admini t r d 
a eith r intramu cular r ub utan u inj ection , mo t commonly every month (B A, 
2012a · B , 201 2b· B , 20 12c; Harri tal. 2009) . Plea e refer t pp ndix for more 
information on th mechani m f ac ti n, indicati n and meth d of admini tration. 
Durati n of ADT remain highl y debated in the literature with regard to intermittent 
ver u continuou treatment (Am ri can ancer ciety, 2014 ). Regardle s of durati n of do ing, 
patient will v ntually become re i tant t h rm ne ablati n and the ca ncer will progre s 
de pite treatment, thi can occur over a peri od of month r year (American ancer ociety, 
2014). Intermittent treatment can be given Dr fi xed period of time, for exampl e 6 month on 
and 6 month off or given based n P A level respon e to trea tment (American ancer ociety, 
2014). Intermittent do ing allow for a break in treatment and thu a break from treatm ent related 
side effect (American Cancer Society, 2014 ). Consensu regarding disease free urvival 
between continuous and intermittent honnone therapy remain unclear, with orne studies 
suggesting continuous hormone ablation ha a small survival benefit (Ameri can Cancer ociety, 
20 14). 
Generally, ADT is used prin1arily for those with meta tatic di sea e; however it ha been 
shown to be effective as nco-adjuvant therapy prior to radiotherapy for tho e wi th high ri k 
localized di ea e (Perlmutter & Lepor, 2007). Additionally, use has be n demon trated in tho e 
with localized prostate cancer, locall y advanced di ase, and those wi th a bioch mica! 
recurrence, such a an increa in P after a pro tatectomy (Perlmutt r & L por, 2007) . 
The clinical benefit of ADT are not onl y related to lowing th progre ion of disease, 
but u e is also a ciatcd with improving ymptom for tho e wi th ymptomati metastatic 
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di ease. For example improvement in pain r lated to bony meta ta e p t void re idual urine, 
urinary ymptoms uch as urgency and frequency and quality of life have been demon trat d 
(Perlmutter & L por 2007). One initia l limitati on to initiati on with ADT i the ' fl are 
phenomenon' whi hi re lated t th initia l urge oft to terone in the body due to the 
timulation ofLHRH receptor (Perlmutter & Lepor, 2007). Thi i mo t frequently prevent d 
with the administration of anti -androgen , which inhibit the effects of testosterone stimulation of 
the androgen receptors (Perlmutter & L por, 2007) . 
Side Effects of Androgen Deprivation Therapy 
Commonly reported earl y adver e effects include hot fl ashes, loss of libido and erectil e 
dysfunction, all of which coincide with achievement of castration levels of testosterone, which 
occurs in only a few weeks (Perlmutter & Lepor, 2007). Prevalence rates of these earl y sid e 
effects vary depending on type of androgen suppression; however rates related to LHRH agonists 
for hot flashes are approximately 40-77%, lo s of libido 100%, and erectile dysfunction 90% 
(BCCA, 201 2a; BCCA, 201 2b). These adverse effects will continue as long as treatment is 
continued (BCCA, 20 12a) . A variety of other side effects that have been documented in the 
literature are outlined in table 1. 
Table 1 Androg n D 'Privation Sid E./f eet 
ataract 
Impaired b ne mineral 
d n ity 
Acute kidney injury 
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(Al- ham i et al. , 20 12; B eb -Dimm r et al. , 2011 ; Braga-Ba aria et al. , 2006; By low et al. , 
200 ; heni er, ubin, & Higano, 200 ; urti , dam, hen, Pruthi , & ornet, 2008; GrunfeJd , 
Halliday, Martin, & Drudge- oate , 201 2; Hanington, Jone , & Badger, 2009; Hervouet et al. , 
20 13; K ating, 'Mall ey, & mith, 2006 ; Lapi et al. , 201 3; van Lond en, Levy, Perera, el on, 
& Green pan, 2008) . 
A comprehensive overview of side effect i provided below, de cribed in relati on to 
physical , cognitive and p ychological side effects. To begin, phys ical ide effect will be 
described in detail in the foll owing ord er: impaired physical function, metaboli c syndrome and 
diabetes, cardiova cular di ease, andropau e, anemia, cataracts, impaired bone mineral den ity, 
and acute kidney injury. This will be follow ed by cognitive ide effects. Lastly, psychologica l 
ide effects, such as depress ion and distress, as well a body image and loss of masculinity will 
then be described. 
Physical Side Effects 
The following physical ide effect will be pre ented below: impaired physical fu nction, 
metabolic yndrome and diabetes, ca rdiova cular di ea e, andropau e, an mia, cataracts, 
impaired bone mineral den ity, and acute kidney injury. 
Impaired phys ical fun ction . Functional decl ine w ith age can o cur natural ly du ~ to 
normal enescent change , however pecific illne e and their trca tmenL, , uch as DT, can 
furth er incr asc de line, which put pati ents at further ri k fo r morbidi ti c. and mortal it . 
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According to yup k yup k Perk and zorak (200 ) t to ter n play an important role in 
mu cle trength a well a th function of the nerv u y t m (B nifazi inanne chi , V lpe et 
al. a cited in oyupek et al. 200 ). uch DT r lated depl eti n in te t ter ne ha 
dem n trat d declin w ndurance, upp r xtremity trength and d terity, a well a elf-
report of phy ica l functi n, r 1 and vitality ( libhai t al. , 20 1 0; yupek et al., 2006) . D pite 
thi knowledge, di cu i n of phy ica l and functiona l decline have not been well de cribed in the 
pro tate cancer literature (Byl w et al., 200 ). 
Metabolic syndrome and diab ete . oldenberg and Punthakee (20 13) defin e metaboli c 
yndrome a at lea t three of the fol lowing criteri a: waist circumference greater than 102 em in 
men or 88 em in women, elevated triglyceride (greater than r equal to I . 7 mmol/L) , reduced 
HDL (le than 1.0 mmol/L in men or 1.3 nuno l/L in women), blood pres ure grea ter than or 
equal to 130/85 and a fa ting gluco e greater than or equal to 5.6 mmol/L. In Braga-Ba aria et 
al.'s (2006) cross sectional tudy, more than 50% of men undergo ing long tem1 ADT had 
evidence of metabolic syndrome. This association is likely related to the profound hypogonadi m 
associated with ADT which has been correlated with an unfavorable metabolic profile such a 
increased insulin resistance, increased body rna index (BMI), and reduced lean body mas 
(Basaria, Muller, Carducci, Egan, & Dob , 2005; Braga-Basaria et al. , 2006). Male 
hypogonadism ha therefore emerged as an independent ri k factor for metabolic yndrome, 
which in itself is a sociated with the development of diabetes and cardiova cular di ea e (Braga-
Basaria et al., 2006; Ford, Giles, & Dietz, 2002 as cited in Braga-Ba aria et al., 2006) . Tsai et al. 
(20 15) confirms the a ociation between ADT and diabete by highlighting three large cohort 
tudies repo1iing an increa ed ri k of diabete in thos with prostate ancer recei ing DT when 
c mpared t non A T u er . Moreover, ADT ha been as o iated with in rea ed total 
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chol terol by up to 10%, triglyc rid by 26% and high d n ity lip pr t in by approximately -
11 %, all f which ha b n dem n trat d within m onth f D initiati n ( aylor, Keating, & 
mith, 2009) . Thi a ociation ugge t ri k trati fica ti n, routine a e m ent f m tab lie 
pr fil e and ardi va cuJar ri k h uld be inc rp rated int pnmary care. 
Cardiova cular di ea e. dem n trated ab ve, DT ha everal adver e phy iologic 
effect , uch a increa ed fa t rna , deer a ed in ulin n itivity, and eleva ted LDL, choJ e ter 
and triglyceride , all of which ar independent ri k fac t r [! r cardiova cular di ease and 
mortality (Ef: tathi u t al. , 2009) . vari ety f tudi e have been done t a certain whether there 
truly i an a ociati n between DT and cardiova cular m rbidity and mortality with c nfli cting 
results. Keating et al. (2006) and ai, D 'Ami co, adet ky, hen and arro ll (2007) tudi e both 
demonstrated an increa ed ri k of cardiova cuJ ar disea e a ociated with A DT, whil e a 2009 
study by Nanda et al. demon trated an increa e in all -cau e mortality in men receiv ing ADT 
among tho e with pre-existing cardiovascular di sease. Efstathiou et al. (2009) did not find the 
same association as their tud y finding were not tati tically significant. 
Andropause symptoms. Asthenia, gynecomasti a, night sweats, hot fl a he , loss of libido 
and sexual dysfunction are collectively known a andropau e symptom (G runfe ld et al. , 20 12). 
These male climacteric symptoms are associated with hypogonadi m and are reported a one of 
the most physically and psychologically bothersome ADT related effects ( runfe ld et a!. , 20 12; 
Nishiyama, Kanazawa, W atanabe, Terunuma, & Takahashi , 2004). !though some of the e 
ymptom may be reported with the normal aging proce , onset of andropau ymptom occur 
quick r and with greater everity in those receiving DT due to the dra tic and rapid drop in 
te tosteron fr m the androgen depleti on of ADT ( run feld et al. , 20 12). The mo t common! 
reported ymptom of andropau ear hot fl a he , wi th up to 0° o of men treated with ADT 
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experiencing this adver e effect ( runfeld et al. , 2012). It ha been rep011ed that hot fla he 
related to ADT ar more frequent , more ever and la t 1 ng r than tho related to female 
menopau e (Grunfeld et al. 201 2). on equentl y hot fla shes andre ultant rught weat can have 
a ignificant impact on daily functioning a both ymptom can hav a negative effect on leep 
which re ult in deleteriou effect with cognitive functioning, dail y accompli hment , 
enjoyment of relationship and activitie , and overall feeling of well-being (Chevalier et al. , 
1999; Roth & Ancoli-Israel, 1999; Leger et al. , 2008 as cited in Hani ch et al. , 2011 ). 
Gynecoma tia a ociat d with hypogonadi m ccur v ry early n in ADT, usually 
within a month or two. Alth ugh not phy i logically ignificant, thi condition can cause 
significant distress and embarrassment impacting psychological well -being. 
H01monal changes related to ADT can ignifi cantly impact exual function. Declin es in 
sexual function were reported a soon as two month after the initiation of ADT and continued 
for the duration of treatment. For those receiving sh011 term or intennittent ADT the negati ve 
effects on sexual function have been reported to last two or more years after treatment 
completion (Gay et al. , 201 3). Impotence, reduced libido and anorga mia are frequentl y reported 
in the ADT literature and are often associated with altered perceptions of masculinity, conflict 
within intimate relationships, a sense of loss of intimacy and ultimately can significantly impact 
the quality of life of both the patient and their partners (Gay et al. , 201 3; Grunfeld et al. , 20 12) . 
Anemia. Anemia frequently occurs in those with cancer, occuning in more than 40% of 
cases (Dicatol, Plawny, & Diederich, 201 0). An association between te tos terone and 
hemoglobin levels have been in the literature since it was first identi fied in 1948 (Hami lton, 1948 
as cited in ut1is et al. , 2008). These findin gs hav been fm1her confi1m d by sev raJ tudi 
with the knowledge that b th urgica1 and phannaco logical ( DT) a tration can impact 
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hemoglobin, often into the anemic range. Thi drop in hemoglobin i likely r lated to the declin 
in androgen and thu lo of th rytlu· poietic timulating ffect of androgen in the bone 
man·ow ( urti tal. , 2008) . Anemia i defined a a hemogl bin le than 14 g/dl in men and 
le than 12 g/dl in women (Dicatol et al. , 201 0) . The r pmi d anemia i n m1ocytic in nature 
with decline in hemoglobin mo t ft n n within three to nine month f initiating treatment 
(Cutiis et al. , 2008) . linical con equence of an mia in men receiving ADT for prostate cancer 
include impaired quality of life a it can contribute to fa tigue and dy pnea on exerti n, but ha 
al o been id ntified a an adver e progno tic factor ( miis et al. , 2008; Dicatol et al. , 201 0). 
Cataracts. Cataract are a chronic, progre ive, age related eye di order that commonly 
affects those over the age of 50 years old (American Academy of Ophthalmology, 20 ll ). 
Without treatment vi ual and phy ical functioning will progre ively decline (American 
Academy of Ophthalmology, 2011 ). Very few tudie are available that discus the as ociation 
between ADT and cataracts. Beebe-Dimmer et al. 's (20 J J) stud y used data from the 
Surveillance, Epidemiology and End Results Medicare Database (SEER) that demonstrated an 
elevation of cataract incidence among those receiving ADT. This association is su pected to be 
related to the onset of other identified adverse effects of ADT such as metabolic syndrome 
(Beebe-Dinuner et al. , 2011 ). 
Impaired bone mineral density. The potential effect of ADT on bone mineral den ity 
has been widely explored in the literature. Those receiving ADT have demonstrated a 5- l 0 fo ld 
increase loss of bone mineral density at multiple skeletal sites that is related to the hypo gonadal 
state induced by ADT. The significant decline in circulating estrogen and t stosterone level 
cause increased rates f bone resorption as well a impairment o f new bone formation ( 1-
ham i et al. , 201 2). hange to bone mineral density can be n wi thi n month of ADT 
initiation, with maximallo n ted within the fir t y ar of tr atment (Al- ham i et al. , 20 12). 
Annual bone loss in the older male population i e timat d to be 1% while bone lo in those 
receiving ADT i more rapid with many tudi e e timating the lo to b 1-4.6% annually 
(Mohile et al. , 2009). Thi lo of bone mineral den ity along ide ADT a ociated d cline m 
lean mu cle mas increa e the ti k of o te poro is, fall and fracture (Nadl r et al. , 201 3). 
Some studies have reported the ri sk of fracture to be as high a 20% by 5 year of ADT 
treatment which is twic th ri k identifi ed in m en with pro tate cancer not receiving ADT or 
healthy control (Nadler et al. , 20 13). Implication of osteoporotic fracture include pain, 
depre ion, fatigu e, functional impainnent, increa e m01iality rate by up to 20% and a 
significant cost to the health care system (Nadl er et al. , 201 3). 
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Acute kidney injury. Recent development in ADT re earch have identified a po sibl e 
connection between the hypo gonadal state induced by ADT and acute kidney injury (Lapi et al. , 
201 3). Lapi et al. (2013 ) highlight that other ADT related adverse effects such as dyslipidemia 
and hyperglycemia associated with metabolic syndrome may impact renal glomerular function 
via the expansion and thickening of the interstitial tubular membrane (La pi et al. , 20 13 ). It is al o 
suggested the vasodilator effects of testosterone are lost when ADT depletes testosterone to 
castrati on levels impacting renal tubular fun cti on (Lapi et a l. , 20 13). Lapi et a l. 's (20 13) case 
control study is currently the only observational tudy investiga ting this association and did 
demonstrate an increased ri k of acute kidney injury with ADT. a result of this relatively new 
finding, data is relatively limited in the literature regarding ADT and it associated effect on the 
kidney, which accounts for the limited data provided here. Nonetheless, thi s side effect must be 
considered [! r this pati ent population. As the above has highlighted, there ar a variety of 
phy ical id efD ct t ADT that mu t b c n id r d when pr viding ar to thi pati n t 
populati n . M ving D rward , the cogniti e effect f 
ognitive ide Effect 
Th D 11 wing will pre ent th f 
Twill b addre ed . 
T n cogniti n . gnitive change 
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have 1 ng been a cia ted with a variety [ can r treatment , h wever education, creening and 
upp rt don t appear to b incorp rat dint cancer care. henier, Aubin and Higano (2008) 
note a p itiv r lati n hip b tw en t t t r n and c gnitive functi n u h a x cutiv 
function , patial m m ry and abiliti . A uch, tudi e have identifi ed the hypogonadi m 
a ociated with DT wa related to impairment in verbal memory, attention and patial abiliti e 
( herri er et al. , 200 ). Furth r, a demon ira ted by herri er et al. ' (2008) tud y, c gnitive 
changes were noted a early and mo t pronounced within three month of ADT and orne but not 
all cognitive change related to ADT might return to ba el ine fo llowing ce sati on of ADT. The 
literature also identifi e that often cognitive changes in tho e receiving ADT are erroneously 
believed to be associated to age rather than the trea tment by both pati ent and provider whi ch may 
be related to a lack of information regarding the potential impact of treatment on cognition. 
Moreover, identi fying cognitive impairments in thi patient popul ation is e entia! as 
impairment can nega tively impact cancer care, outcom , trea tment tolerability and pati ent 
decision-making (Mobile et al. , 201 0). Fina ll y, the psychological ide effects and their impact on 
health and well-being will be di cu ed below. 
Psychological Side Effects 
Th p ychol gica l equelae o f A DT, uch a depre ion and di tr 
b dy image and los of masculinity w ill be pre en ted. 
fo llowed by altered 
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Depre ion and di tre . The overa ll pre alen of d pre i n in th e with cancer i 
e timated t be b twe n 15 -25%, while th rec 1Vll1g DT ar prop ed t b at an ven 
higher ri k ba d n cun- nt r ea r h ( I, 2014 ). How er d pit it preval nee, d pre JOn 
and di tre are und r r cogniz d and undertr ated whi h can impact m dical adherence, 
increa ed morbidity and p ibly m rtality (Pirl, iegel, de, mith, 2002; Hen111ann et al., 
1998 · Richard n et al., 1990; pi egel Kat , 1996 a cited in Pirl et al. , 2002). Du t the 
potential impact, th id ntifi ca tion and tr atmcnt f p ychologica l i u related to cancer and it 
treatment have become increa ingly id ntifi ed a an important a pect t c mprehen ive cancer 
care (Vodermaier, Linden, & iu, 2009) . More v r in an attempt to increase reporting f 
psychological issue and le en the tigma a ociated with p ychologica l c nditi n , terminology 
has shifted from language uch as depre sion, p ychiat1ic, emotional or p ychosocial i sue to 
the term di tre . The link between testosterone depletion and depre ive yrnptoms wa fir t 
identified in 1995 , however ince there ha been confli cting re ults of the impact of ADT in 
relation to mood disorders (Hervouet, avard, Iver , & avard, 20 13 ). Animal model have 
demonstrated altered neurotransmitter levels, such as serotonin with low y temic testo terone, 
which can negatively affect mood ( aini et al. , 20 13 ). Further, studi es involving elderly, non-
cancer patients have demonstrated an as ociation between low te to terone and depre 1ve 
ymptoms that resolved with testosterone honnone treatment (Saini et al., 20 13 ). 
Altered body image and lo s of masculinity. Body image can be defined a "the 
dynamic perception of one's own bodi ly appearance, function, and en ati n a vvell a ~ eling 
a ociated with thi perception. It occur larg ly at a ubcon ciou I vel and i normall 
regulated by the condition f the body'' (Dropkin, 1999, p . 10 a cited in Harrington, Jones , 
Badger, 2009). van (200 1) a c ited in li [[e (2006) note men traditional! pia 'e a hi gh valu 
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on pecific qualitie and characteri tics uch a phy ical trength and the id al male b dy, which 
is intricately connected with embodied rna culinity. Therefor adv r e changes to bod y 
ae thetic , uch as brea t t ndem e and enlarg m nt and th 1 f p nile length and volume 
can create ignificant p ychological di tre ( aini et al. , 201 3 ). ther lit rature ugge t that 
ADT related change a oc iated w ith dec line in te to terone, uch a · ~ minine behav iour ' like 
hot fla she and mood change are ema cul ating and wor en If-image and perception ( ziefula, 
Grunfeld, & Hunter, 20 13). Wor ening self- image and perceived los of masculinity can be 
further perpetuated by other effects of ADT treatment, uch a declining libido, energy, body 
shape, ability to work (Harrington et al. , 2009). avon and Morag (2003) as cited in Harrington 
et al. (2009) identify the e changes to body image can crea te emotional distance in intimate 
relationships impacting the quality of life of both partners. Provided above is a comprehen ive 
de cription of the phy ical, cognitive and psychological side effects of ADT highli ghted in the 
literature. The next chapter, research and methods, will provide a de cription of the literature 
search that was completed in order to answer the research question. The process, such a the 
identification of search terms, inclusion and exclusion criteria, and creening and earch 
outcome will be described. 
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hapter Tw 
Re earch and Method 
Th g al of th literature ear h wa t an wer the qu tion : r P practicing in a 
pnmary car etting, what creening i required to id ntify ide effect f Tin men with 
pr tate cane r. arch t rm [! r the literature review w re elected a th y repre ent the va ri u 
term applicable t the que tion being ar h d . arch term included prostate cancer, pro Latic 
neopla m, androg n ablativ therapy, andro n deprivation th erapy, primary car w; essm nt , 
screening, and fo llow up . ln order t narr w the earch and yie ld finding r levant to ADT and 
creening of ide ffect , a combinati n of teJm were elected, using ubj ect heading and the 
Boolean phra e 'and ' . For exampl e, androgen d 'Privation therapy and patient assessment, 
androgen deprivation and creening, androgen deprivation and screening /or side effects. 
androgen deprivation and fo llow up. However, very few finding accumul ated from thi earch 
critetia, therefore lightly broader search term such as androgen deprivation therapy and side 
effects, depression and androgen deprivation therapy, anemia and androgen deprivation 
therapy, metabolic yndrome and androgen depriwttion therapy, and sexual dy.~function and 
androgen deprivation therapy. The inclu ion and exclusion cri teri a applied con i ted of the 
following : 
Tabl 2 lnclu ion and Exclu 10 11 rit ria 
lnclu ion riteria: 
No limitation to dat f publi h d paper 
Arti cle writt n in th ngli h language 
Men with pro tate cancer (all ethniciti e ) 
No limitation to ag r tag of di ea 
Included at lea tone tudy group re iving andr gen depriva tion therapy (ADT) 
Both quantitative and qualitativ tudie were included 
Published paper were n t limited t anada alon due t limited earch re ult 
Primary care etting 
Exclu ion riteria: 
Publi hed paper without recommendation for creening/a e ment of side effects 
Acute care 
urvivorship care 
lnclu ion criteria included men with pro tate cancer (a ll ethni cities), however wa not 
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limited to age a ninety- even percent of all prostate cancer di agnoses occur in those over the age 
of 50, however some individuals are diagnosed at a younger age (Prostate Cancer Foundation, 
20 14 ). All stage of disease were included. Further, the search was not limited to recent stu die 
as the effects of androgen suppression have been reported in the literature since Huggin and 
Hodges' initial stud y of androgen depri va ti on in the 1940 ' (Perlmutter & Lepor, 2007) . 
Treatment with ADT was included in all tudi es, however election of tudies wa not limited to 
prostate cancer patients receiving ADT alone in order to allow for compari on of adver e event 
between other treatment modalities and healthy control s. Both qualitative and quantitative tudy 
d signs were included in order to identify a broad account of DT ide effects and them , 
identify how these ide ef~ ct were screened in a re earch capacity, and wh ther the method 
of screening such a va lidated creening tool may prove relevant or be recommended for 
clinica l practice a ses ment of side effects . ualitative studie were specifically considered as 
open nd d que ti n all w d £ r d cripti r f1 cti n n ide ffect which may identify 
further adv r ef£ ct r th me that h uld be c n ider d D r ere ning but may n t be 
id ntified thr ugh quantitative de ign . 
A anadian guideline and literature were limit d, inclu ion criteria includ d ther 
countrie . verall, inclu ion criteria remained broad a data pertaining t creening and £ llow 
up wa limited . Br ad crit ria a! all wed for the ability t ga in in-depth in ight into adver e 
event related to DT in order to highlight gap in creening in primary care. xclu ion 
included article that did n t provid creenmg rec mrnendation for primary care, acute care, 
po t treatment care and £ 11 w up ( urvivor hip) . 
The literature earch began with a earch of the fo ll owing four electroni c databa e : 
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Cochrane library, INAHL, Pubmed and Joanna Briggs ln titute Library. The majority of the 
searche utilized medical ubj ect headings in order to facilitate appropriate data retri eva l by 
accounting for various terminology and ubject matter for the topic of interest (Na tional In titute 
of Health, 20 12). Ba ed on the above earch terms, a total of 1198 at1i cles were identifi ed . 
Us ing the University of Northern Briti sh Co lumbia 's library re ources for direction, a 
search of the grey literature was then done. This included a search of the following: clinical 
practice guidelines and protocols for British Columbia, Canadian Nurse A ociation tandard 
and best practices, anadian Medical Association InfoBase, National Guideline learinghou e, 
anadian Agency for Drug and Technologic in Hea lth and tandard and uideline Evidenc 
( A ). Guidelines were canned and included in the earch re ult if they included any a pect 
of screeni ng, recommendation or follow up. oogle cholar and the World Wide Web were 
also searched u ing the ame earch ten11s and phrases a above. The earch revealed an 
additiona l 140 potentially relevant material . inally, the reference list for all full text eligible 
paper were cam1ed and a total of three additi nal paper were identified. In the end a total of 
1341 potentially relevant mat ria l were id ntified, retriev d and exp tied into ndnote. 
Screening and earch Outcome 
The literatw· review id entifi d a t tal of 1341 potentially r levant paper . After 
ere ning titl and ab tract for uitability, thi number wa nan wed down to 50 arti cle for 
further review. Full tex t article were then reviewed, 28 of which were excluded ba ed the on 
inclu ion and exclu ion criteria . After thi proce , 22 eligible papers w re available for review 
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( ee Appendix B fo r flow chart). The next chapter will di cu the findin g of the 22 papers 
identified in the review . Thi will begin with twelve individual research studies, fo llowed by five 
clinical practice guid eline , four clinical review and one editorial. 
hapt r Thr 
Finding 
The arch trategy d ribed ab ve identified 22 miicle to a i tin an wering the 
re earch que ti n: r P pra tieing in a primary car etting, what ere ning i r quir d t 
identify ide effect in men with pr tat anc r rece1 mg T. The £i 11 wing chapter will 
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pre ent 12 individual re earch tudie , u ing b th quantitative and qualitative de ign to provide 
in ight into pecific creening r co1run ndati n . The lit rature frequ ently de cribe ADT ide 
effect by a focu n phy ical, c gnitive and p ych logical alteration of function; therefore data 
from the individual tudie will b pr sented in a imilar fa hion. Following individual tudy 
finding , the finding from five cunent clinical practice guideline , four clinical review and an 
editorial will be analyzed with regard to recommendation for creening for those receiving ADT 
for prostate cancer. Finding from clinical practice guideline , clinical review and editorial s are 
deliberately pre ented a a whole rather than through individual phy ica l, cognitive, and 
psychological side effects in order to demon trate the gap , limitations and str ngth of each. 
To begin, cunent recommendations for screening of phy ical, cognitive and 
psychological side effects from 12 individual research studie will be highlighted. everal topi c 
are noticeably ab ent from the e studies, such a follow up interval , cardiovascular disease, 
cataract and acute kidney injury, which account for the diver ion from previou ly organized 
paper subheadings . However, recommendation for these topic are de cribed in other re earch 
materials, such as clinica l practice guideline , clinical reviews and editorials, which will be 
pre ented 11 llowing individual studie 
Phy ical ide ffects 
Phy ical fun ction . r the 12 r ea rch tudic revt wed, onl y one tudy described 
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phy ical and functional impairment with creening reconunendation . By low et al.' (2008) 
study inve tigated the prevalence of fall , phy ical and functional impairment in tho e receiving 
ADT for ymptomatic meta tatic pr tate cancer. Fifty patient over th age of seventy w re 
rectuited from a convenience ample of men being treated at the Univer ity of hicago 
Genitourinary Oncology clinic . 11 patient underwent a comprehen ive geriatric as es ment at 
baseline, which was then repeated after three month of ADT treatment (only 40 patients had the 
repeat as essment a 10 patient were lo t to D llow up) . The comprehensive geriatric as essment 
included an assessment of functional mea ures, risk for functional decline, physical fun ction, 
history and risk of falls, mental status, nutritional as essment, social supp011, and fatigue using 
tools that have been validated in the elderly population. Functional measures such a activitie of 
daily living (basic elf-care), instrumental activitie of daily living (activitie required to live 
independently such as banking, meal preparation and hopping), and the Vulnerable Elder 
Survey (YES) were done to assess risk of functional decline. The YES is a 13 item, self-reported 
screening tool used to identify geriatric patient who are risk for functional decline. Physical 
function was assessed using the Short Physical Perfonnance Battery ( PPB), which assessed the 
physical function of the lower extremities through three tests of balance, gait speed and 
quadriceps strength. The other tools utilized in the geriatric assessment included the Short 
Portable Mental Status Questionnaire, Charlston Comorbidity Index, Medical Outcome tudy 
Social Supp011 Scale, the Mini Nutritional Assessment, and the Medical Outcome tudy hmi 
Form 36 item health survey. Deficits were noted in balance, walking and chair stand in 56% of 
patients, 24% had impairments on activities of daily living while 42% had impainuent in 
in trumental activitie of daily living. At bas line, 22% of patients had reported fall within the 
previous three month and 56% noted additional fall after trcatm nt had been initiated . a 
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re ult of the in rea d ri k for fall , th tudy auth r id ntifi ed a need for routinely crcening D r 
abnormal phy ical p r£ rman and ri k for fall in thi patient p pulation. maJOr tr ngth to 
thi tudy i th u of to 1 that have been alidated £ r u e with the elderly populati n. 
Howev r, due to a mall ample ize and the nature f the cr ctional tudy, a t mporal 
relati n hip between DT, abnonnal phy ical performance and fall c uld not be reliably 
establi bed r gen ralizable. 
Metabolic yndrome and diabete . Two individual re earch tudies id ntifi ed m tabolic 
syndrome and diabete a ide effect to ADT. A cro ecti onal tud y by Ba aria et al. (2005) 
evaluated the ffect of long term ADT u eon fa ting gluco e level , in ulin level and in ulin 
re istance in men with prostate cancer. Three group were tudi ed : roup 1 con isted of 18 m en 
with prostate cancer who were receiving DT for 12 month prior to the tudy, group 2 included 
17 men with non-meta tatic prostate cancer who had not received ADT, and group 3 wa made 
up of 18 healthy controls. Parameters such a age, race, and BMI were documented along with 
objective measures of total and free testosterone levels, Jeptin, fa ting glucose and insulin level 
Leptin is involved with long tenn regulat ion of energy balance, sup pres ion of food intake and 
weight loss (Klok, Jakobsdottir, & Drent, 2007) . However, intere tingly, obes individual 
typica ll y demonstrate high Jeptin levels, which uggests leptin re istance (Klok et al., 2007). 
Fasting glucose refer to a erum blood ample that refl ect the gluco e (sugar) concentration to 
which the body tissues are expo ed (Hess-Fischl, 20 15) . Insulin i a hom1 ne produced by the 
pancreas that allows the body to u e glucose deri ved from food intake for energy or to tore 
gluco e for future use (He -Fischl, 20 15) . levation in fa ting glu o e level demon trate the 
bo ie , inability to produce enough insulin r th e development o f in ulin re istan e, both or 
which in rea e the ri k f developing diabete , (He -Fi chi , 20 15) . 
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ignificant negati correlati n wa n ted b tw e n tc t ter n and fa ting gluco e, 
in ulin and leptin level . dditionally, m n wh had r c ived Thad high r fa ting glue e 
le el when compared t the n n DT gr up (p=O.O 1) and the c ntr I gr up (p<O.O I). In ulin 
le el were al o mu h higher in the T gr up ( 45 - 7 .25 u /m ) in c mpari on to 24.0 +-
7.24 u /mL in then n T gr up (p=0.05) and 19.0+- 7. 9 u /mL in the control group 
(p=0.02) . Finally leptin leve l wer al higher in the DT gr up when c mpared t the n n 
ADT group (p<O.O 1) and c ntr I gr up (p<O.O I) . Thi tudy dem n trated that tho wh 
received long term ADT were at increa ed ri k [! r developing in ulin re i tance; h wever re ult 
may not be entirely generalizabl e a the maj rity of ubject were auca ian. The u e fa non 
ADT and control group doe however help account[! r any influence pro tate cancer and aging 
may have on metabolic parameter . onethele , tudy author identifi ed individual on long 
term ADT, greater than 12 month , be creened [! r hyperglycemia or eleva ted blood uga r . 
Tsai et al.' (20 15) retrospective cohort study up port th above findings with regard to 
insulin re i tance through demonstrating the p tential to develop di abete r lated to thi 
treatment regimen. A total of 12,191 participant with localized pro tate cancer between the age 
35 and 100 were recruited between 1995 and 200 . Participant were identifi ed from one of thr e 
health care delivery y tern within the HMO ancer Research Network. The e y tern ollect a 
variety of data regarding inpatient and outpati ent diagno is, clinical en ount r , laboratory 
values, tumour regi try and pharmacological di pen ation. Men with pro tat cancer w r 
included if they received DT within one year of diagno i , did not have diabete , or had not 
had a pr tatectomy, radiati n or chemotherapy ne year after diagno i . Data regarding diabetes 
diagno i wa btained from inpatient and outpati nt diagno i. cod , diabete. medi ' ations 
prescribed and hem gl bin value . f the 12,191, 22° o ( ~64 ) rccci\ ed DT v. 1thm one 
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y ar f diagn i and the remaining 7 % (N=9543) did n t r ceiv DT. tudy finding 
dem n trat d 9.9% ofpati nt d vel p d diab te during D 11 w up, whi h wa a median of 4 . 
year . Incid n rat w r 2.4 p r 100 p r n in th T group and 1.6 ev nt per 1 00 
p r on in th non-primary DT group . cia ted with the incidence f diabet 
includ d tr atment with DT after 12 m nth from pr tate cancer diagno i , hyperten i n, and 
obe ity. 
A are ult of finding , tudy auth r reinD rce the n ed t creen thi s pati ent p pulation 
for in u1in re i tance during DT trea tment. More ver the tud y author id ntify the Am erican 
Diabete A ociation (ADA) gu ideline a a method for creening, however encourage m re 
frequent monitoring for tho e receiving ADT. A noted by the ADA gu idelines, 
recommendation D r creening of the general public i uggested via a erum hemoglobin A 1 , 
fa ting blood gluco e and a 2 hour po t prandi al blood ugar every three yea r among any 
individuals who are overweight (BMI >25), obe e (BMI >30) or over the age of 45. For those 
receiving ADT for prostate cancer, stud y authors identify creening should occur prior to the 
initi ation of ADT and then repeated annually. 
Study strengths include use of a c ntrol group, a large sample size and a long period of 
fo llow up . Further, potenti al cofounding effects such as age, race/ethnici ty, year of diagno i , 
comorbidities and health pl ans were adjusted fo r. However, there i no mention as to whether the 
study controlled for all ri sk factor associated with diabetes. Three stud y limitation wer noted 
with the fir t being p tential for selection bia given the study de ign wa an ob ervationa l tudy. 
ec ndly, a hemoglobin A 1 of 7% was u ed to e tabli h the di agno is of diabctc rather than 
the 6.5% which may have mi ed ome partic ipant with early di abet s . Fina lly, a the 
partic ipant were elected from the l-IM y tem gcn rali zability to non-HM system. ma be 
limited as HMO likely promote and upports prevention and early detection of diab te . 
Andropause syndrome. f th 12 individual r earch tudies, only one pecifically 
looked at andropau e syndrome in relation to creening rec rmn ndation . Through qualitative 
interviews, Grunfeld et al. (20 12) expl red the prevalence and impact of andropause ympton1 
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in men with meta tatic pro tate cancer underg ing ADT. Twenty-one patients were rec1uited and 
underwent emi- structured in per on or t lephone interview. Interview que tion were 
developed based on previou re earch, and discussion with a urology nurse specialist, 
psychologists and urologi t. Interviews were conducted using open ended question , with loo e 
structure that focused on area of predefined intere ts uch a side effects of ADT and coping 
strategies, however allowed for discussion of issues as they emerged in the interviews. Four main 
side effects to ADT were identified, gynecomasti a cogni tive decline, change to sexual function, 
hot fl ashes and night sweats. Approximately half of the patients reported gynecomastia and or 
breast tenderness, while 71% expetienced night sweats and hot flashes, all of which were a 
source of emban assment. Night sweats also significantly contributed to di sturbed sleep patten1s 
which resulted in daytime sleepiness . 
Additionally, reported changes to sexual function such as interest and physical capability, 
varied depending on the patients age and marital status. For example, sexual dysfunction uch as 
impotence or reduced libido was more commonly accepted in those that were single or if their 
partner had a low libido. Others deemed sexual dysfunction to be a major concern, particularly 
related to concerns about di sappointing their wives, while others discussed the impact on 
masculinity. Di sclosure of ymptoms was variabl e, with most limiting disclosure to close family. 
Surprisingly this study found many of the participants had a de ire to corm11ence e ual acti ity, 
however very few had received treatment for erectil e dy function (ED) or were of:D red 
coun lling ither £ r them lv or th ir intimat pat1:n r . Thi lead one to c n id r whether 
pati nt are being ad quately cr en d for ual dy functi n . Ba d on he itancy t di cl 
andropau ymptom , tud y auth r mpha ized th importan Ii r the P P to a k ab ut ide 
effect to a i t m n in actively and op nly di cu ing b th r m e concem . tudy tr ng th 
include an appropriat ized ample gr up with an adequat number of m aningful and 
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de criptive qu tati n that mpha ized th ccurr nee and meaning of DT ide effect . 
Additionally, interview que ti n app ared t b evidence ba ed and pi! ted which allowed £ r 
gathering of pecific in£ m1ati n ught by the tud y author and participant were a! o pr vid ed 
an opp 11:unity to di cu th r i u allow ing for the potenti al development f n w them e . 
Limitation may include limited infotmation regarding the interviewer , such a age and ex 
which may alter participant 'willingnes to di clo e sen itive i ue . 
Anemia . nly one research stud y identifi ed anemia as an DT re lated ide effect in 
conjunction with creening recommendations. urti e t a l. ' (2008) r tro pecti ve chart review of 
metastatic pro tate cancer patients receiving ADT attempted to confinn the as ociation between 
anemia and ADT and identify whether patients were clinicall y symptomatic with their an mia . A 
total of 135 ca es were reviewed, all of which had received some fon11 of ADT. Case review 
included treatment type (single or combination ADT), hemoglobin and mean c rpu cular volum 
(M V) levels prior to initiating ADT followed by mea urements of the e three and nin month 
after starting treatment. Patient chm1: were reviewed to asses Ii r reference noting the pre enc 
of ymptom logy related to anemia ( uch as dy pnea and fatigue) . f the 135 chart re iewed, 
43 patients had laboratory data uffici nt to be included in the final analy i,. dec line in 
hem globin value , by - 1.11 g/dL, wa noted in all patient r cciving DT (p 0 .001 ). Nom1al 
hemoglobin va lue for men are appro imately 1 .2 t 17 .5 g/d , mean value or hemoglobin 
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prior to DT treatm nt initiati n wer 14.12 g/dL while value b tween thr e and ix m nth 
rev al d a h mogl bin valu in th anemic range (1 .0 1). M V 1 v 1 al o dem n trated a 
decline at ix month , with a volum of 9 .5 fL. Finally, 7% ( 16 out f 2) patient exp ri need 
ymptom of anemia. maj r limitati n t thi tudy wa that many of the pati nts received a 
vari ty of ADT treatment th refore the chang t hem globin c uld n t b olely attributed to 
one method of ADT alone. Ba ed n the tudy finding al ng ide imilar tudy finding from 
prevwu tudie it wa ugg ted by tudy author to creen for anemia and its ymptom after 
tarting ADT, although pecifics ar not included. 
Impaired bone min eral den ity. Three f the twelve tudi e reviewed looked at bone 
mineral den ity. Yu eta!. ' (20 12) tud y demon trate the e hanges thr ugh inv tigating the 
change in bone mineral density and fracture risk with intermittent treatment with ADT. Fifty-six 
patients with non-metastatic prostate cancer were recruited for the study. Pati ents were treated 
with nine months of ADT and then di continued until pro tate pecific antigen (P A) reached 1 
ng/mL for those who underwent a radical prostatectomy and 4 ng/mL for tho e who underwent 
radiation and ADT. When the e PSA thresholds were met, ADT wa reinitiated for another 9 
months of treatment. Dual energy x-ray absorptiometry (DEXA) scans, CT can , bone 
scintigraphy and lumbar spine x-ray were done prior to stmiing ADT and repeated with each 
ubsequent change in therapy (beginning and end of each treatment) . Of the 56 patient , 3 8 had 
n nnal ba eline bone mineral den ity. f the 38 patients with normal ba eline re ult , 13 .2° o 
developed o teopenia during ADT treatment. Further, re ults d monstrated an 80° o deer a e in 
b ne mineral density of the spine and 56.4% decline in bone mineral d n ity of the 1 ft hip 
during the fir t treatment period . Additionally, bone mineral density reco er of the pme wa 
een during the fir t off treatment period , with an average ' hange of 1.4%. Unfortunately, 
veral patient dropped out of the tudy due to DT treatm nt failure which may limit th 
tati tical p wer f there ult . R ult may al b influ need by individual bi 1 gic and 
nvir nm ntal factor . Alth ugh n t pecifi d ifD X can w r ped rmed with different 
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machine at different facilitie , the malJ incon i t nci c uld p tentially influ nee the re ult 
a w 11. Ba ed on variability of b ne mineral den ity change through ut trea tment period and 
the known ft ct of DT, continu d and r gular monit ring with 
by the author of the tudy. 
can wa id ntified 
Ba d n the well documented effect of DT on bone density in the literature, Al- ham i 
et al. (20 12) examined care gap with regarding to creening, prevention and trea tment f 
osteoporo i in men with prostate cancer receiving DT. Thi retro pective tud y consisted of 
men with non-meta tatic pro tate cancer who received ADT betwe n 2008 and 2009. Patient 
were selected ba ed on treatment at the J uravin.ksi ancer Centre in Hamilton Ontario and 
identified by their hormonal therapy treatment billing number. A total of 149 men' chart were 
reviewed and data such a age, date of prostate cancer diagnosi , stage of di ea e, and la t P 
value were documented. Risk factors for osteoporosis such as previou fracture , 
hyperthyroidism, use of corticosteroids, diabete , smoking or alcohol use wa a! o obtained. 
Finally, presence of osteoporo is screening characterized by a baseline or ubs quent dual x-ray 
ab orptiometry (D XA) was documented. Study re ult detetmined a large population of 
participants had risk factors pre ent foro teoporosi , with five parti cipant having previou 
fractures, 13 .3% alcohol abu e, 49.3% had a hi tory of moking, 16.7% were cuiTent ' moker , 
3.3% had a hi tory of cortico teroid use and 2% had a hi tory of hyperthyroidism. Ba elin 
D XA can wer d ne in 58 .8% of men receiving T and 20 . 0 o of which had repeat 'can. at 
some point a ~ llow up . nly 28% of participant had both a ba elinc and follow up X 
can. ftho cr ened at ba lin 12 w r ~ und to hav a bon mineral den ity in th 
o t op rotic range (T c re of -2.5 r gr at r) and 1 pati nt had aT c rein the teopenic 
range ( -1 to 2.5). It wa al o found that th e with increa d number f ADT inj ection were 
more likely to be creened while age, tage r P at initial vi it did n t impact creening. 
It i noted by the tud y auth r that ere ning ~ r teop ro i with tool , such a the 
World Health rganizati n fractur ri k a e m nt t 1 ( RAX) a well a a ba eline D XA 
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can prior to ADT initiati n h uld be con idered. tud y findin g w re limited to data being 
retrieved from a ingle cancer center that may impact generalizability. Further, data was obtained 
fro m a retro pective chart revi w; therefore data may not accurately refl ect the clinical care 
patient received. trength include an adequate di cu ion regarding implica ti ons for practi ce a 
well as pecific recommendations that may c ntribute to improved care for thi patient 
population. A mentioned above, although the data wa obtained from one care center, data 
found in thi cunent study was supported by other tudies done in other in titutions that as i tin 
validating the study findings . 
Similarly, Morgans, mith , O'M all ey, and Kea ting (20 13) asse ed bone den ity te ting 
among men with prostate cancer receiving ADT for one year or greater. Men were identified 
from the Surveillance, pidemiology, and End Re ults ( EER) which i a National ancer 
Institute program that collects data from cancer regi tri es in the United tate . Patient selected 
were diagnosed between 200 1 and 2007 and over the age of 65 . Jtimately 28 ,960 men were 
elected with local/regional di ease. Men with meta tatic di ea e were excluded from the tud y 
a bone mineral density te ting in this population i not reliable . Bon den ity tc. ting data wa 
documented six month before DT initiation for a total of 1 months . Rc 'ult demonstrated 
only l 0.2% of tho e receiving DT [! r more than one year had bone mineral density tes ting 
43 
done 6 m nth prior to ADT initiation t ne year aft r tr atm nt. Rat f creenmg 111 rea ed 
over tim a 14.5% f m n wh initiated T in 2007-2008 had b ne mineral den ity te ting 
ver u 6% ftho e wh tarted DT in 200 1-2002. urther, ld er men (over ag 5) had Je 
bone mineral den ity t ting d ne than th e in the 66 t 69 ag rang a did black m n ver u 
white men and tho e with I wer educati nal atta inm nt. tud y auth r continue t ndor e b ne 
den ity creening and enc urag additional ef£1 r1 t pr m te creening. 
trength f the tudy include a large ample ize, m derate 1 ngth of [! 11 w up , and 
broad patient characteri tic which would ace unt for genera li zability. Limitation however 
include timing of the tudy, a the study began prior to signifi cant evidenc in the lit rature 
regarding ADT's effect on bone hea lth. Therefo re, limited knowledge of ri k likely impacted 
the very low creening rate in the arly year of thi s study. econdl y, recommendation for 
testing by PCP versu patient refu al to complete testing wa not able to be d tennin d. Further, 
testing was done in those enroll ed in Medicare therefore par1icipation in testing ma y vary 
depending on medical coverage. 
Unfortunately, the literature failed to identi fy a large number of studi e di scussing 
specific physical side effects alongside screening recommendation for many of the ide effect . 
This i true for physical function, metaboli c disea e, di abetes, andropau e and anemia, with only 
one study found for each . In this case, one mu t be cautious when interpreting there ult and 
consider tudy methods, design and number of participants which can limit or trengthen study 
findings . For example, Tsai et al. (20 15) and Morgan et al. (20 13) tudy' included very larg 
sample with long follow-up, which helps toe tabli h creditability of tudy re ult . he nc, t 
cction wi ll pre ent tudy finding related to the cognitive ide iTect f DT. 
ogni tive id e ffect 
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Although ev ral tudi have been conduct d t id ntify DT effe t on cognition, only 
one tudy wa identifi din the literature arch that m et the inclusion and exclu ion criteria for 
thi review. Mohi le eta!. ' (20 1 0) tudy ught to identify the prevalence of cognitive 
impainnent and change to c gnitive per£ rmance over tim in thirty- tw m en with pro tate 
cancer receiving ADT. A vari ety of tandardi zed neuropsychol gical a es ment t ol were u ed 
to as e s attention, language verbal memory vi ual memory, visuospati al planning and motor 
proce ing. The e tool were pecifically elected ba ed on th ir es tabli bed reliability, validity 
and ensitivity . Asse ment tool included were: The Trail M aking te t (attention), Di git pan 
(attention), Controlled Oral Word As ociati on Te t (language and emantic fluency) , T he Rey 
Complex Figure Te t-Copy Trial (visuo patial planning) , Hopkins Verbal Learning Test-Revised 
(verbal memory), Brief Vi ual Spatial Learning Test-Revi ed (vi ual memory), Grooved 
Pegboard and Finger Tapping tests (motor peed and dexterity) , Becks Depression lnventory-2 
(depression), and The State Trait Anxiety Inventory (anxiety). Assessments were done by a 
trained psychometrician within two weeks of starting ADT, and repeated ix months later. 
Surptisingly, at the time of baseline m easurem ents 45% of participants scored grea ter than 1.5 
standard deviations below the mean on two or more neuropsychological measures, with no 
changes in cognition noted after treatment initiation. However, 3 8% of the to tal cohort 
demonstrated a decline in executive functioning at the six month assessment. Based on the e 
findings study authors suggest pati ents be screened for cognitive impaim1ent prior to 
considerations of ADT and possibly throughout trea tment regimen , particularly if pati ents are 
more vulnerable to developing life altering conditions such a dementia . 
tudy strength include con idering potentia l cofound r such a an i ty, d pr ion and 
education. Limitati ns include a hart fo llow up time of 6 month which leave long tem1 effect 
of ADT till unknown. Further limiting the tudy r ult i p or completion of follow up 
a ment with only 65 % of m n c mpl t d th p t tr atment D llow up evaluati n , which 
may have impact d there ult . dditi nally, th mall ample ize with ut the u e fa control 
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group limited the tudie ability t identify the impact [ T n c gnitive change . The e stud y 
finding ma y be u ed in c njun ti n with ther finding in th literatur which ugge t DT 
impact cognitive function . The p ych logical ide effect of D were identifi ed in three 
individual re earch tudi e and will be presented below. P ych logical ide effect include 
depre ion and di tre foll w d by alt red b dy image and lo of ma culinity. 
Psychological Side Effect 
Two tudie identifi ed depre s ion and di tre a DT related id e effect . Lee et al. , 
(20 14) longitudinal tudy aimed to identify depressive symptomology in men receiving ADT for 
non-metastatic prostate cancer. Participants were recruited between September 2008 and October 
20 12 as part of a larger study examining quality of li fe in those receiving ADT for pros tat 
cancer treatment. The sample con i ted of three group : 6 1 patient with pro tate cancer 
receiving ADT, 6 1 patients with pro tate cancer not receiving ADT (instead a radical 
prostatectomy) and 61 healthy control . ach prostate cancer patient receiving ADT wa 
matched to a participant in the non ADT group (prosta tectomy) and con trol group . elf-rep rt 
questionnaires were completed by all participants with the fir t qu tionnaire done prior to the 
initiation of ADT and again six month later. Depressive ymp tomology w ere a s d u ing a 
validated tool call d the enter for pidemiological tudies Depr ion cale (C -D) . With 
thi mea ure, score range from 0 to 60, with scores above 16 indicating clinicall y ignificant 
depres ive ympt ms. 
tudy re ult revealed an incrca c in dcpre ive symptomology (p 0.05) and in ·rcas 'd 
rate of linically ignificant d pr 1v ympt mol gy (p<O.OO l) in the DT group between 
ba line and follow up a e ment . Rate f depre ive ympt m 1 gy D r the DT gr up at 
ba elin were tati tically ignificant at 2 %, c mpared t the n n DT group (5 %) and contr 
group (1 2%). t the ix month follow up a e ment, the DT group r po1ied d pre ive 
ymptomology rate f 39%, while the n n DT and c ntr I gr up had rate f 9% and 11%. 
There wer two limitation to thi tud y; fir t the tim b tween a e ment wa brief, onl y ix 
month which doe n t allow for 1 ng term impact of ADT to be adequately a e ed. econd, 
overall tho e in the DT group had a poorer progno i ; therefore it i po ib le the depre ion 
rates were related to awarene of progno i rather than the effect of ADT. Moreover, it i 
poss ible that increa ed depre sive symptomology i related to ADT related ide effects, such a 
hot fl ashes. Con equentl y, study author recognize identifying and treating symptom of 
depres ion hould be a priori ty in the research and practice domain , h wever suggesti on for 
screening are not provided by the author. 
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Pirl et al. (2002) repOJied similar findings in their tudy. Foriy fi ve pati ent with prostate 
cancer were recruited, all of which were receiving ADT, either alone or in combination wi th 
chemotherapy. Patients were clas ified according to fon11 of ADT (GnRH agoni st or 
orchiectom y), re pon e to treatment ( table or progre ion), andr gen dependent or independent, 
treatment w ith concuJTent chemotherapy (yes or no) and hi story of depre sion (ye or no) . 
unctionaJ status wa assessed using the Kam of ky Perfon11ance ca le (KP ) which ha b en 
hown to have good reli ability and validity (Heiru·ish & anz, 1984 ), while the B ck 
Depre ion Inventory (BDI), a va lid reener ford pres ion, and tructured linical Interview 
for 0 M-IV ( ) wa u ed to a c for dcpre ion and dys thymia. Fatigue wa a. scs eel 
u ing the ati gue verity ca le, a 7 it m ca lc a liclat d in cvcra l population such as cancer, 
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mu ltip l c l r i , Parkin n ' and fibr myalg ia with e c II nt va lidity and internal re liability 
(Neuberger, 2003 ). 11 a ment wer admini ter d by a trained regi tered nur e. The author 
report d, the mean KP core wa 91 , indicating a high level of function. lth ugh there wer 
no ca e of new n et d pre i n n ted in th ample, 12. % of men r c iving DT were found 
to hav m aj r d pre iv di rder a a e d by the ID. Thi tati tic i eight tim the 
national rate f depre ion in men. Furth r BDI re ult dem n trated 13.3% f m n r p rting 
mild to moderate depr ion with no report f moderate to evere d pre ion. However, result 
hould be viewed with cauti on a other vari able r lat d t d pre i n could confound the data. 
Further, a the maj rity f pati ent were identifi d a high functi ning, r p rted rate of 
depre ion may not be generalizable to tho e w ith severe di ea e and poorer functi on . Due to 
stud y finding , the authors emphasize the need to provide appropriate and regul ar a e sment fo r 
depression to this patient population. 
Body image and loss of masculini ty . ne tudy identified altered body image and lo 
of masculinity as an ADT related ide effect whil e meeting the inclusion and exclu ion criteri a. 
An exploratory, descriptive non-experimental study by Harrington et al. (2009) de cribed 
change to body image in those receiving DT for the trea tment of prosta te cancer. The tudy 
consisted of 132 men, all over the age of 60 repre enting all fo ur tage of prostate cancer. The 
sample was divided into two group , with 66% receiving ADT and 34% who had never received 
ADT. The Body Image cale (BI ) wa used, which i a t n- item sca le that measure change to 
b dy image in cancer patient . cores ra ng from 0-30, with hi gher core identifying greater 
degree of b dy image di ati sfacti on. Unfortunately, the tud y doe not mention wheth r th Bl 
is a validated t ol, however tudy findin g demon trat the Bl to have a ceptable p ychometric 
pr pert ic to upp Ii it c ntinued u in men wi th pro tate an cr. era ll , the mean scores in 
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the ample w re .13 out f th p ible 0, with th m an c re f the DT group being higher 
(X=2.23 , D= 1.44) than the non DT expo ure gr up (X= 1.52, D= 1.44 ), dem n trating 
greater body di ati faction in the D group . Th high t area of di ati fa cti n p rtained to 
percepti n of exual attra tiv ne , ma culinity, and ~ ling le wh Ie a the re ult f body 
change . A p itiv c IT lati n wa n t d betw en b dy image di ati fa cti n and a hi gher BMI. 
Author sugge t P P anti cipate change t exuality and intimate relation hips and 
should creen, educate and provide tr atm nt ~ r the area of health . tudy str ngth include 
implication for practi ce a well a provide relevant informati on int potential intervention t 
aid in relieving di tres in thi area, uch a di et and nutritional erv ice that have been deemed 
uccessful in female brea t cancer pati ent and men with pro tate cancer receiv ing ADT. A 
limitation to the stud y however i age a all men were 60 years or older, which doe limit the 
information to thi age group . Previous studi e on female breast cancer pati ent have 
demon trated ignifi cantly more distre s regarding body perception in younger populations 
which lends one to consider whether this may prove true for younger men with pro tate cancer, 
however tllis study ample does not allow for thi con ideration. 
In summary, these 12 re earch studies indicate that DT has the potential to cause a 
variety of complex and multi-dimensional side effects. However, de pite the acknowledgement 
of these potential ide effect , individual res arch tudi es provide very few recommendation 
with regard to specific method or interval ~ r creening ide effects to ADT. Many 
recommendation are imply compri ed of bl anket tatement to encourage creening howe er 
remain overall ambiguou . or exampl e, of the five de cri bed phy ical ide effects, onl two 
tudie provided spec ific recommendation wi th regard to m thod and interva l for screening. 
imilarl y, meth d of creening for cognit ive impairment and d pre, ion ar " not pre, entcd . 
More ver, many f the initially defined id ef~ ct pr vided in the backgr und , uch a 
cardi va cular di ea e cataract , and acut kidney injury are notic ably ab nt a the literature 
earch failed to pro id any re earch tudie that included r c mm ndati n [! r cr ening D r 
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th e ide ef~ ct . Finally alth ugh a vari ty f t 1 are pre en ted a m th d fa ment in 
the r arch tudie them elve very few tudi e ac tuall y adv cat [! r the u f pecific 
creening tool or propo a m thod of a e ment. ln the upcoming paragraph , ere nmg 
reconunendation from five clinica l prac tice guid line will be pre nted. 
Current Clinical Practice Guid elin e 
Clinical practice guid lin are vidence ba ed, y temati cally devel ped 
recommendation and tatement which are de igned to support practitioners in decision making 
regarding health care and clinical circum tanc (Watter , 20 15). urrent clinical practice 
guidelines regarding the screening and management for men receiving ADT are quite limited in 
the literature. Five clinical practice guideline were identifi ed in the literature earch, one from 
Alberta Canada, the United States, and Au tralia and two from Europe. All fiv gu ideline were 
developed through a critical evaluation of evidence found in the literature via a y tematic 
literature review and through expert consensus and clinical interpretation (Alberta Provincial 
Genitourinary Tumor Team, 20 13; Australian ancer Network, 20 1 0; E U, 20 15; C , 
2015a; NI , 20 14). Findings pe11aining to the five pe11inent gu idelines are discus db low. 
The only anadian guideline that appear to be avai lable com from th Alberta 
Provincial enitourinary Tumor team, publi hed in 2013 . R comm ndation include follov up 
within three t ix months of initiating therapy and a clinically indicated (Alberta Provincial 
enit urinary Tum r Team, 201 ). uration for follow up i noted a 'age dependent' , \\hich 
doe not provide a pecific referenc for P P ( lbe11a Provincial enitourinary Tumour Team, 
50 
2013). Further, Albe11a Provincial Genitourinary Tumour Team (2013) propose ADT u e over 
ix month to be a high risk factor for the development of o teoporo is , therefore thi guidelines 
ugge t all patients have a ba eline dual energy x-ray absorptiometry (D XA) can prior ADT 
initiation. It i al o identified that patient should undergo as e sment of fracture risk using the 
World Health Organization FRAX tool (Albe11a Provincial Genitourinary Tumour Team, 2013) . 
The econd guideline to be reviewed was publi bed in 20 15 in the United States from the 
National Comprehensive ancer Network (N 20 15a) . Thi guideline provides a brief 
overview of the work up and diagno is for prostate cancer, management for low, intennediate, 
high risk and metastatic di ea e including a variety of treatment modalities . In terms of ADT 
very little infmmation is provided regarding screening. The only specific endorsement presented 
is for the National Osteoporosis Foundation's recommendation that all patient with pro tate 
cancer receiving ADT be assessed for fracture risk using the Fracture Risk Assessment (FRAX) 
tool. It is further suggested that those who demonstrate an increa ed risk based on the FRAX 
assessment should undergo a DEXA scan p1ior to ADT initiation followed by a repeat scan after 
one year of treatment (NCCN, 2015a) . Finally, screening for and prevention of cardiovascular 
disease and diabetes are also mentioned in the NCCN guidelines, however it is highlighted that it 
is unknown if strategies for screening and prevention should differ from the general population 
and therefore no formal suggestions are made (NCCN, 20 15a). 
The Australian Cancer Networks guidelines were published in 2010 and pe11ain to the 
management of locally advanced and metastatic prostate cancer. The guidelines di scuss 
prevalence and possible treatments for side effects of ADT uch as depression, anx iety, and 
osteoporosis but do not provide recommendation around screening. Statements such a "hen lth 
profes ionals should be aware of risk factor forth development of anx iety and depression and 
be pr par d t treat appr priate ly" (Au tra lian an r etw rk, 20 I 0, p. 1 J) are included with 
no di cu i n a t meth d r fr quency of creening. therwi e, the only clear 
recommendation r ~ r to b ne mineral den ity mea ur ment pri r t initiating DT and 
ubsequently during the treatment with the po ibility fin tituting pr ventative mea ure 
(Au tralian ancer etw rk, 201 0) . 
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The ational In titute for Health and are xperi nee ( I ) guidelin originate in the 
United Kingdom with it mo t recent revi ion occurring in 20 14 . Rec mmendation include 
creening for fatigue and exual dy function, how ver no method , tool or frequ ncie are 
provided. Recommendation are made however t con ider creening for fracture ri kin men 
initiating long term (>6 month ) ADT (NIC , 20 14 ). It i al o end or ed by the I E (20 14) 
guideline that men rec iving ADT hould have acce to erectil e dysfunction enrice , PD 5 
inhibitors and psycho exual coun elling, however methods and frequency of creening are n t 
provided. Additionally, it i recommended that as e ment for gynecoma tia i done within the 
first month of treatment with ADT in order to offer appropriate treatment such as prophylacti c 
radiotherapy or tamoxifen (NICE, 2014 ). Algoritluns for diagnosi of cancer and treatment are 
provided, however screening algorithms are not included. 
Finally, the fifth guideline to be reviewed comes from the uropean A sociation of 
Urology ( AU) Prostate Cancer guideline . Thi guideline was publi hed in 200 1 and mo t 
recently updated in 2015 . The AU (20 15) guidelin s address follow up, p ycho logical coping, 
as well as laboratory and diagno tic investi gation for screening for diabetes, anemia, r nal 
function, and bone mineral density. linical follow up is empha ized a mandatory for all 
patient receiving ADT ~ r the trea tment of prostate cancer. Al though p cific recommendation~ 
for timing and m th d of creening are made, it i , noted that follow up 'hould be tai lored ba ed 
on individual ymptom , treatment modality and progno tic factor . enerally, follow up 
appointment were recommended for 3-6 months after ADT initiation followed by timed 
interval depending on tage of di ease. For example, th e with no evidence of meta tatic 
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di ea e were recomm nded to be revi wed in clinical follow up every ix month with a [! cu on 
evaluation of ymptom , re p n e to tr atment and side effects, digi tal rectal examination and 
recormnended lab screening. Tho e with meta tatic di ea e should be evaluated as described 
above, however follow up hould occur every three to ix month . Moreover, it i ugge ted that 
those with adequate treatment re pon e a PSA of 4 or le , improving ymptoms, and evidence 
of psychological coping can be reviewed at longer period such as every six months. Finally, the 
G8 screening tool is sugge ted as an adjunct method for evaluating the health status of older 
adults with prostate cancer. This geriatric creening tool is designed to assess overall health 
status, with results identifying whether pati ents should receive the arne treatment as younger 
patients or if patients are vulnerable to impairment thus requiring a more thorough assessment or 
alteration in treatment. 
The EAU (20 15 ) also provides guidance for specific laboratory studies based on stage of 
disease and individual comorbidities. All patients receiving ADT are uggested to undergo both 
PSA and testosterone screening with each follow up visit. The P A i identified as an important 
marker for following the course of prostate cancer, as change to PSA levels help identify 
response to treatment and can also identify complications of treatment. A rise in P A is often 
seen prior to the onset of clinical symptom by everal months. Testosterone is monitored 
regularly to ensure patients achieve initial castration goals ( < l nmol/L) and to en ure thi level i 
achieve in order to control di ease progr 1011. ther reconu11endcd laboratory tests for all 
patients receiving ADT include a fasting gluco and hemoglobin a well as fa ting lipid , 
both ugge ted to be done at ba eline and then r peat d ev ry three months . Vitamin D and 
calcium may al o be considered. For tho e with meta tatic disea e, laboratory creening is also 
recommended to include h m gl bin cr atinine and alkaline phosphata e. Hemoglobin i 
reconunended in order to creen for anemia which commonly ccurs after three month of 
treatment. reatinine is ugge ted to identify i ue related to renal function uch a bladder 
retention or ureter ob truction while alkaline pho phata e help identify the livers response to 
the di ea e proce and treatment. 
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Diagnostic imaging, in the form of a bone mineral density test i identifi ed as an 
important intervention to a e ri k for osteoporo i and thu i sugge ted for all those receiving 
ADT by the EAU (20 15). Bone mineral density tes ting is suggested by the EAU (20 15) to be 
completed two years after castration and then repea ted annuall y if osteoporosis risk factors or 
every two years if no risk factors . Finally, for those with a hi story of cardiova cular di sea e or 
those over the age of 65 years old, consultation with a cardiologist prior to ADT initi ation i 
recommended. Similarly, those with impaired glucose while on ADT warrants a referral to an 
endocrinologist. 
Although the EAU (20 15) guideline does provide some excellent recommendations it i 
incomplete. For example, screening recommendations for physical function , cognition and mood 
are not specifically identified . It is only briefly suggested patient be screened for p ychological 
coping however suggestions as to what PCPs are to creen for, such as mood changes, depression 
or body image concerns are not provided nor are methods or frequency of screening. Other 
commonly noted symptoms associated with ADT uch as andropau e and e ual dy function are 
n t addre ed. 
In utrunary, the guide lines avai lable for P P providing suppm1 to patient with prostate 
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cancer r ceiving ADT are limited. Although orne app ar to be more comprehen ive than other , 
it i apparent that none of the available guideline creen for all or even half of the documented 
side effect of ADT. The imp Iiance of bone mineral d nsity te ting wa c n i tently id ntifi ed 
in all guideline with recommended method f ere ning which i helpful for P P ; however 
variabilitie in frequency were noted. The remainder of T ide ffect are sporadically and 
incon i tently addre ed. M reover, the language in which recomm ndation for creening are 
vague in term of pecific uch a tool and frequency. Interestingly only two of the five 
guideline recommend p ychological creening, two di cuss screening for exual dy function, 
two mention cardiova cular creening, one di scus es cognitive changes and only one addre se 
andropause symptoms. Moving forward , creening recommendation for follow up and ADT 
related side effect will be presented from four clinical reviews. 
Clinical R eviews 
Clinical reviews are concise, up to date atiicles intended to provide health care providers 
with updates of recent development and accounts of a specific topic. Reviews aim at providing 
clinical applications to both primary and secondary care (The BMJ, 20 15). Four clinical reviews 
will be presented by Saylor et al. (2009), Saylor and Smith (20 13), Wilkinson, Brundage, and 
Siemens (2008) and Mobile et al. (2009). Saylor et al. (2009) completed a clinical review which 
focu sed on reviewing the c01runon and recognized side effects of ADT with recommendation 
for prevention and treatment. Recolllinendations include creening for diabetes, cardiova cular 
di ease, osteoporosis, and hyperlipidemia and were adapted based on commonly accepted 
guidelines such as the American Diabetes As ociation (AD ), Am rican Heart A ociation 
(AHA), National steoporosi oundation (N F) and the Nationa l hole terol Education 
Program Adult Treatment Panel III (N P A P Ill) . The authors mphasiz d the lack of 
evidence ba ed guid line and r earch tudie that~ cu on creening and management of 
pro tate cancer pati nt receiv ing DT and ugge t thi i related to ADT hazard being 
relatively n wly identifi d but not fully defined. Bon mineral den ity te ting i rec mm ended 
for tho e r ceiving medication in which increa e ne ri k f bone lo , uch a DT, at 
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ba eline prior to initiation of tr atm nt, repeated one y ar after ADT treatment and then every 
two year or a clinically indicated. creening D r pre-diab te or di abete i recomm nded in all 
tho e receiving ADT, tarting with a ba eline mea urement pri r t initiation of treatment and 
then annually. Fa ting pla rna gluco e i the creening te t propo ed, with serum level of 1 00-
125 mg/dL considered po itive. Hem gl bin Al C i not recommended for the di agno is of 
diabetes in thi review. Fa ting lipoprotein areal o recommended at ba eline, within the fir t 
year of ADT treatment and then every five year or a clinically indicated. Further, 
recommendations include assigning a target LDL based on cardiova cul ar ri k factors and 
projected risk category as outlined in the NC P ATP III guideline. According to this guideline, 
dete1mining proj ected cardiovascular ri sk involves determining erum fa ting lipid levels, 
establishing risk based on cardiovascular risk factors and pre ence of atherosclerotic di ease, as 
well as establishing category of risk with the Framingham risk calculator (National In titute of 
Health, 2001 ). Based on all this criteria , a LDL target goal i e tablished and interventions such 
a lifestyle or phatmacologic can then be considered. Of note, persistent conce111s have evolved 
regarding the validi ty and reliability of the ava ilable cardiova cul ar a e ment tool , including 
the Framingham ri k asse sment ( ff et al., 20 14 ). However, the tool continue to be upported 
by a variety of cardiovascular organization and guideline to aid in risk di cu ion and de ' i ion 
making ab ut life tyle and pharmacal gica l preventative intervention ( off eta!., 2014 ). 
Noticeably ab ent from this clini al revi w i di cu ion or re ommendation regarding phy. ical 
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functioning, andr pau e ymptom , anemia, ca taract acute kidney injury cognitive change or 
mood change related to DT. 
aylor and mith (2013) revi wed metab li e complicati n of DT, pecifically obe ity, 
in ulin r i tance, and alterati n in lipid . vidence r garding incidence of ide effect a well a 
recommended manag ment i pr vided. H we er very little is pre ented in regard to creenmg. 
Author ugge t method of cr ning fi r pre-diabete and diabete ace rding to the American 
Diabete A ociati n (AD ) guideline . Diffi ring fr m the D guideline h wever i the 
ugge ted interval for creening, a auth r ugge t tho e receiving ADT to be at high ri sk for 
insulin re i tance, thu ugge t y arly a es ment via a fa ting pla ma glucose (preferred) or a 2 
hour 75 gram oral gluco e tolerance te t for diagno i . La tl y, creening and management of 
lipids ba ed on N EP A TP III guideline i encouraged. 
A third review completed by Wilkinson et al. , (200 ) examined ava ilable re ource for 
PCPs to provide appropriate follow-up for patients with prostate cancer. It identified the role 
PCPs have with regard to providing care to this population, but highlights the pauci ty of 
information regarding fo llow up . Accordingly, a brief overview of the incidence of pro tate 
cancer in Canada, available treatment modalitie and indication , rec01nmendations for P A 
monitoring (either during therapy, after primary therapy or during active urveillanc ) and 
expected PSA respon es to treatment is pre ented . Mo t relevant i the algorithm provided 
regarding the care for patients with systemic di ease on ADT. !though thi algorithm i not 
comprehensive it does provide some guidance to P P . Recommendation in lude follow up 
vi it with family phy ician every ix months in which clinical inquiry, management of treatment 
related ide effects, and P te ting hould b con idered . Further, bone mineral densit testing 
i end or ed every two year while n DT and a bone scan if P leveL rise abo\ c 20 nm mL 
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or when linically indicat d . 
In th fomih and final rev iew, M hil et al. (2009) reviewed the manag m ent of 
androgen deprivation complicati n in m en with pro tate cane r. Thi r view provide a detailed 
backgr und regarding pr tate cane rand ADT a well a detail d ummary f comm n ide 
effect to ADT uch a an mia h t fla h , depre i n , exual dy functi n cognitive change , 
physical function, metabolic yndr me, cardiova cular di ea and b ne mineral den ity 
impainnent . ugge tion for creening and management are provided for a elect group of ide 
effects. However the creening recommendations pre ented are relatively ambiguou , 
nonethele an empha i on creening for depre ion, cognitiv change , phy ical function , 
metabolic yndrome, cardiova cular di ea e and bone mineral densi ty are included . For example, 
recommendation included in this review simply state m en receiving ADT should be creened 
for depression and other mental hea lth problems, however fail to prov ide guidance on method 
or intervals for screening. Slightly more specific are recomm endation for cogniti ve impairment 
screening, which is suggested ptior to the initiation of ADT and throughout treatment. Although 
methods of screening are not provided for cognitive a e sm ent, rational e for creening is 
highlighted, suggesting regular creening can prov ide valuable information regarding underlying 
deficits which can negatively impact cancer care, outcome , treatment tolerability and patient 
decision making (Mobile et al. , 2009). 
For those with pre-existing metaboli c or cardiova cu lar disea e or risk factor for 
cardiova cular disease, Mohile t al. (2009) ugge t patients b a ses ed prior to th initiation of 
ADT a well as c n ider referring uch patients to a cardiologi t. Moreover, for tho e with 
cardiova cu lar di ea e, routine te ting is ugge ted to evaluate worsening of under! ing di , asc. 
Mean r intervals for a ses ment are not included in the review . 
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Th m t d tailed r c mm ndati n in thi re iew i [! r o t oporo i creening (Mohile et 
al. , 2009). Recomm ndation includ a full hi t ry and phy ical xamination pri r to tarting 
ADT t a e for te p ro i , fall and fra ture . urth r cr ning for b n 
mineral den ity via a D XA can 1 r c mmended pri r t T initiation and then ev ry 6-24 
month depending on ri k fa ct r and ba line b ne mm ral den ity. It al o app ar a careful 
as es ment f overall h alth tatu i recommended prior to the initiation f ADT and throughout 
treatment to ' include e ami nati on f d main that could exacerbate pre-exi ting condition and 
accel rate mortality'' (p. 15) how v r d tail regarding method of exam, tool or frequency are 
not included (Mohile et al., 2009). 
In summary, the available clinical review provide an array of infonnati n regarding 
pro tate cancer incidence, prevalence, side effect to ADT and suggested management of effect 
but do not lend them elve to comprehensive creening recon1111endations for adver effect of 
ADT. Similar to clinical practice guidelines, some of the above clinical review are more 
comprehensive than others, although none of the reviews provide inclusive recommendations for 
screening of all ADT related side effects. Although frequency and interval of creening were 
variable in the recommendations, half of the review adapted their recommendations from 
clinical guidelines such as the ADA and the NC P A TP III. The mo t consi tent ere ning 
recommendation were related to bone mineral den ity, metabolic yndrome and cardiova cular 
disease, all of which were emphasized to orne degree in three out of th four review . Moreov r, 
only one review propo d screening recommendations for depre ion, on eli cus d cognitive 
impairment screening and ne acldre eel diabete creening. The final comp nent of thi chapter 
wi ll present rcc mmenclation for crcening from an ditorial id ntified during the lit rature 
earch. 
Editorial 
Medical journal edit rial are h rt aiiicle r e ay that e pre the view and pmwn 
of th auth r . dit rial pr ide per pectiv n a pe ific t pic f intere t, ft n r lated t a 
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re arch or review articl publi h d in the am journal i u ( teven , 2006) . In thi ca. e, J ne 
(20 11 ), a con ultant phy i ian and end crin logi t relea eel an edi t rial in the Briti h Medica l 
Journal eli cu ing the ca rdiova cular ri 
highlight th accumulating evidence t ugge t 
ciated with DT. hi editorial fu1iher 
1 a cia ted with adver e ffect n 
cardiova cular ri k factor , cardiova cular event and po ibl e m rtality. However it i noted that 
not all tudy re ult concur with the e finding f increa eel ri k f m rbidity and moiiality. It i 
believed that the a ociation and 1i k of ADT and ca rdiova cular eli ea e will become more 
apparent with time. De pite the inconclu ive finding , an advi ory tatement from the American 
Heart A ociation, American ancer ociety and the men can rological As ociati n ha be n 
released with recomn1endation that all patient receiving treatment with ADT be een 
periodically for follow up assessment of cardiova cular ri k factor , and en ure tho e with pre-
exi ting cardiovascular eli ease have their econdary prevention treatment optimized . 
Furthe1more, on the basi of the cun ent evidence and potential for ri k the U F d and Drug 
Admini tration have made change to the label on gonadotropin relea ing h01mone agonist . 
Recommendations advoca te for P Ps to monit r pati ent for sign and ymptom ugge tive of 
cardiova cular eli ea e a we ll as the periodi monit ring of blood gluco e or glyc ylated 
hem globin (U. Food and Drug ociation, 20 l ). 
The increa eel prevalence of metabolic yndrome and metabolic effect of DT arc a! o 
noted , therefore, patients are recommended periodic foil w up with th ~ir P P.. uggcs tion , 
include a r vi w of cardi va cu lar ri k fa · tors artcr thre ~to si month , and th nat least 
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annually. Furth r r v1ew f lipid 1 wering tr atment, anti -hyp rten ive medicati n , gluco e 
low ring treatment and antiplatel t therapy i indicated wh n appr priate. xtra vigilance i al o 
recommended for tho b ing trea ted with in ulin for diabete a a tud y by Haid r, Ya m, 
a ad and hab igh (2007) a cit d in Jone (20 ll ) id ntifi ed DT may negatively affect 
glycemic control . 
ln ummary, the re ear h ha demon trated a lack of clear, c n i tent, comprehen ive 
recommendation and gu idelin . Availabl gu ideline and rev iew have attempted to addre 
creening for adver e effect of DT however rec mmend ation fo r creening do not materiali ze 
into a comprehensive guide for P P . Recommendation are vague in nature, a pecific 
regarding methods of creening or frequency are either incon i tentl y provided or not provided at 
all. Furthermore, all gu idelines and review fail to addre all ide effect including a blatant lack 
of reconlffiendation for common adverse effects . Thi variability in recommendations likely 
reflect the lack of definitive evidence available on thi topic (Mclnto h et al. , 2009). What i 
also apparent from the finding i a lack of uptake or adherence to the few screening 
recommendation that are available. Finally, it is identified that although ind ividual research 
studies are focusing on ADT related side effect , very few provide impl ica tions for practice with 
regard to screening which explains the exclusion of a significant number of studie in the 
literature search. The fo llow ing chapter will discuss the r search finding previou ly analyzed 
combined with upplementary research to info rm evidence ba ed recommendation for creening 
of AD related ide effec ts. 
hapter Four 
Di cu sion 
The re earch de cribed in the Finding hapter has af£ rd d in ight into the re earch 
que ti n regarding ere ning £ r men rec 1vmg DT £ r pro tat cancer. This chapt r will 
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ynthesize there earch finding in t rm f curr nt recommendation for creening prac tice 111 
tho e receiving ADT as to what hould be creened, how to ere n, and intervals for creening. 
Rec01runendation for practice will then be pre en ted based on a consolidation of the literature 
and upplemented with evidence ba ed guideline to info rm ugge ti n for creening and care. 
Recommendations will be organized according to each side effect identifi ed under the physical, 
cognitive and psychological health domain. pecific creening strategic and interval of 
assessment will be propo ed. Futihermore, an overview of rec01runendation will be pre en ted in 
order to provide PCPs with a quick reference for creening for this pati ent population. The 
chapter will finish with a brief discussion on recommendations fo r education and research. The 
recommendations below are not intended to replace clinical judgement but rather inf01m 
practice. Therefore, recomn1endations should be con idered in conj unction with individual 
patient circumstances. 
Clinical Practice Recommendations 
To begin, general fo llow up recommendations will be propo ed. Clinical practice 
recommendations for each physical, cognitive and psychological ide effect will then be 
presented to include both methods and interva l for screening. 
Follow up. linical fo llow up is an important aspect of managing patients with can r. 
With re pect to monitoring men with pro tate an r rec iving DT, common obj ctive for 
follow up include m nitoring r ponse to trea tment, en uring complian e with treatment, 
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d t cting complication f th rapy, and a e ing and managing palliative ymptom (Mottet et 
al., 20 15). Howe er, th literature r al recoll1ln ndati n for fi 11 w up in thi patient 
population are limited and incon i tent. Very fi w re arch tudie , clinica l practice guideline r 
review tre the importance of provid r regularly a ing pati ent or pr po e 
rec mmendation form th d or frequency f fi 11 w up . Th .. A (20 1 5) illu trate the mo t 
detailed recommendati n and tre clinical follow up i ab lutely mandatory for tho e 
pre cribing and or managing tho e receiving DT fi r pro tate cancer. It is empha ized that 
regu lar follow up allow the provider to a the pati ent' current condition, check for po ibl e 
trouble orne ide effi ct to tr atment a w II a ymptom of di ea e, a 'neither bi o logy nor 
imaging modaliti e can replac face to face c linic vi it ' ( A , 20 15 , p . 100). 
Although ome author , uch a Wilkinson et al. (2008) and the AU (20 15) ugge t 
pecific screening tests to occur during follow up , such as a digital rectal examination and 
laboratory te ts, the majority of findings demon trate broad and vague recommendations, such a 
statements that encourage evaluation of ymptoms and side effects of treatment without 
providing specifics (EAU, 20 15; Mohile et al., 2009; Wilkinson et al. , 2008). Vague 
recommendation uch a these require PCP to have in depth know ledge of screening for DT 
related ide effects and health ri ks in order to as e the patient properly. Thi limitation leave 
P Ps guessing as to which side effect to address and how to best screen for the e i ues . 
As always screening should be individualized, based on age, ymptoms, co-morbidities, 
treatment modality and progn i ( A , 20 1 5). !though optimal level for follow up are 
variable in the literature, ranging from tru·ee to ix months, ba ed on the above finding it is 
rec mmended patient be reviewed within three month of initiating DT, and then eYer three 
to ix m nths (Albe1ia Provincial enitourinary umor cam, 20 l ; U, 20 15; Wilkin. on et 
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al., 2008). During the e fo llow up appointment it i critical that patient be reviewed thoroughly 
to monitor for di ea e and treatment r lated i ue . pecifically, follow up should include a 
phy ical exa1nination, creening of ymptom and ide effects a w 11 as laboratory 
mea urements, all of which are de c1ibed below with detailed recoffilnendation . 
Physical function. creening of phy ical functioning is only briefly mentioned in the 
literature findings . It is propo ed by thi pap r that thi may be due to the as umption that P Ps 
frequently screen patient functioning a a basic aspect of appropriate p1imary care. Nonethele s, 
it is difficult to infer from blanket tatements such a 'careful asse sment of overa ll health tatus' 
used in Mobile et al. 's (2009) clini cal review, whether this includes screening of physical 
functioning. Mohile et al. (2009) does however provide sli ghtly more specifi c recommendations, 
suggesting patients be assessed prior to ADT initiation for risks for falls, which one could 
assume would include measures of functional tatus such as balance and mobility. Regardless, 
the mention of physical assessment without specific recommendations related to intervals or 
screening methods does not provide PCPs with clear guidance. Interestingly, By low et al. ' s 
(2008) study was the only study to investigate the impact of ADT on physical function with a 
variety of validated and reliable tools; however the study recommendations, did not recommend 
any of the tools used in the study for the screening of physical functioning in patients on ADT. 
A functional status assessment, a component of a comprehensive geriatric assessment, i 
commonly utilized in a variety of settings, including the By low eta !. ' s (2008) tudy as well as 
theN CN (2015b) clinical practice guideline in oncology for older adults . Thi tool will be 
proposed by this paper as a tool for physical function screening in those receiving ADT. The 
a essment can be completed via self-reported measures, uch as one's ability to carr out 
activities of daily living (ADLs) and instrumental a tiviti of daily living (lADLs) or through 
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phy ical p rfi nnanc m a ure uch a th Tim d p and (T )tet(N N ,2015b).The 
fo llowing c mpon nt hould b includ d in the functional tatu a 
Tabl 3 Functional A sment 
f daily living (A ): 
d, gr ming, m bility, ability 
ind p nd ently and 
continence. 
Ability to perform in trumenta l acti viti e of dail y 
living (IADL ): pr paring mea l , d ing hou work, 
h pping, managing money and u ing the 
tel eph ne. 
Performanc tatus: via Ka1nof: ky or 
(http ://oncologypr .e mo.org/ uid eline -
Practice/Practice-Tools/Performance- cale ) 
Fall : A e for falls in the Ia t 6 months or fear of 
falling. For tho e who have exp rienced a recent 
fall (within 6 month ) or have a fear of falling, 
consider additional evaluation with: 
• Physiotherap y or occupational therapy 
as es ment 
• Assess Gait us ing the TUG test (see CCN, 
20 15b for test specifics) 
• Checking and replacing Vitamin D level 
when appropriate 
• Refer to geriatric 
(N CN, 20 15b). 
Idea ll y a functional status assessment would be done by th e onco logist or urologi t 
during the diagno tic and treatment planning process, regardle P P should con ider a ba elin 
functi nal tatus asses ment and repea t thi s a sessment through ut treatment in order to identify 
change t phy ica l statu or functioning . Interva l f ere ning hould be ba ed on the patient , · 
age, co-morbiditie and vera ll hea lth tatus, ideally occu lTing at I a t ever 6-1 ~ month .. 
Moreover, a full functional a ment i not alway. required a. a brief s · reen ing or phy, ical and 
fun tiona! abilitie can c ur during regular follow up vi it by ob erving mobility and ga it a 
the pati nt mo e thr ughout th lini c e am r 111 . 
Metabolic disea e and diabete . creening il r in ulin re i tance and diabete 
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included a a r comn1endati n in many clinical practi ce guidelin , clinical review and 
independent re arch tudie ba d n ignificant ev idenc that DT increa e in ulin re i tance 
and therefore incidence f diab te . T ai et al. (20 15), ayl r et al. (20 13 ), and ayl rand mith 
(20 13) all refer to the American Diabete ociation ( ) guideline for their 
rec01nmendation with regard to method f creening, however interval pr p ed by the e 
authors differ from AD guideline and from each other. ADA gu ideline uggest creening 
intervals ba ed on lev 1 of ri k, for example th without ri k factor be creened every three 
years and tho e with ri k factor hould be screened more frequently. Currentl y, DT or 
hypogonadism is not noted to be a risk fact r for diabet s in the ADA guidelines, but it appears 
the majority of study author , including Tsai et al. (20 15), aylor et al. (20 13 ), and aylor and 
Smith (20 13) consider the risk to be high enough to pur ue more frequent screening. Moreover, 
the majority of tudies anticipate diabetes or insulin re istance a a potential issue by 
recommending ba eline creening in the form of laboratory work be considered in all patient 
prior to ADT initiation. 
As n ted above, the majority of re earch article on thi topic adapt their cr emng 
recommendation from the ADA, however, a thi paper serve to infom1 care delivered by P P 
within anada , anadian guide lines from th anadian Diabete A ociation (CD ) will b 
pre ented . Ba ed on th increa ed risk demonstrated in th literature, tho e undergoing ADT for 
prostate cancer with or wi thout other ri k factor hould undergo screening prior to DT 
initiation and repeated annua lly. Method of reening hould include a fa ting pia ma glucose 
( P ) or h mogl bin A1 ( k e, Punthak e Ran m, Prebtani & ld nberg, 201 ). 
Additi nally, ri k fa ct r :D r diab te h uld b a e ed pri r to DT and r peated annually, 
ee the DA guid lin fr m koe t al. (20 13) :D r p cifi c ri k factor . 
The a e ment fi r metab lie yndr m i imply ba ed nth diagno tic criteria noted 
by oldenberg and Punthakee (20 1 ) ab v . M ea urem nt uch a blood pre ure hould be 
obtained at ba line and repeat d with ach :D 11 w up a ment. ther mea urement uch a 
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wai t circumference hould be btain d ideall y at ba el ine and at lea t annu ally in order to 
monitor chang and adequately a e ri k. FUiiherm re interval for creening hould follow 
the above recommendati on fo r insulin re i tance that recommend yearl y creening with either a 
FPG and/or A1 . Fa ting lipid creening recommendation will be di scu ed below and hould 
be implemented for thi patient popul ati on. 
Cardiovascular disease. There is accumulating evidence to ugge t ADT can negati ve ly 
impact ones cardiovascul ar health. The con·e!ati on between ADT and cardiova cul ar di ea e i 
uggested to be related to effect on varying cardiova cular ri k fac tors impacting the likelihood 
of cardiovascular events and possible motia lity (Jones, 20 11 ). As Jones (20 11 ) highli ght 
however, there is no con en us that tlli as ociation trul y exists, however in light of the potential 
for increased morbidity and mortality, consideration of cardiovascul ar health i recommended in 
a mall minority of cl inical practice guideline and reviews ( A , 20 15, Jone , 20 11 ; Mobile et 
al. , 2009; aylor et al. , 2009; Saylor & mith, 20 13 ). Otherwise, creening recommendation 
with regard to ADT and it assoc iation with cardiovascular hea lth are omewhat li mited in the 
literature, pa1iicularly in individual re ea rch tudie . 
P tenti al trategies to minimizing morbidity and mortality include a hared care approach 
between P P and p c iali ts. For example, P P , hould routin -ly a scss patient. for 
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cardiova cular ri k fact r , monitor for ign and ympt m f ca rdi va cular di a e, revi w 
cunent cardiova cular treatment , and refer or con ult when pre-exi ting di ea e or c ncen1 are 
id ntifi d ( A , 20 15 ; J n , 2011 ; M hile et al. , 2009) . It i anticipated that with time and 
further r earch, new data will guide cardi va cul ar cr ening rec mm ndation for tho e 
receiving ADT. In the meantim , the litera ture i not c nclu ive a t whether creening 
trategie for the pro tate cancer popul ati n rcc iving DT hould differ for the g n ral 
population (N N, 20 l5a) . A uch the premi e of the maj rity f availabl e recomm ndation 
tern from theN EPA TP III guideline which are di cu ed in detail in the findings, which 
focu e on identifying and categorizing ri k and dy lipidemia creening and m anagem ent 
( aylor et al. , 2009; aylor and mith 20 13 ). What remain unclear is how oft n creenmg 
should occur, as this vari e between study recommendati on . 
Anderson et al. (20 13 ), authors of the most recent anadian ardiova cu!ar Society 
(CCS) guidelines provide recommendation that are clo ely aligned with the NCEP A TP III 
guidelines referenced by many of there earch fi ndings in the literature. A uch, the 
guidelines will provide the basis for cardiovascul ar screening recon11nendation in thi paper. 
Screening should begin with a hi tory and physica l examination, idea lly completed prior to ADT 
initiation and then routinely asses ed during follow up as previously de cribed. The hi tory 
should include screening for cardiovascular ri sk fa ctors such a : moking, diabete , hyp rten ion, 
family hi story of hyperlipidemia or prem ature cardiovascular di ea e, chronic kidn y di ease, 
inflammatory bowel di ea e, HIV, PO, abdomina l an ury m , erectil e dysfunction and obe ity 
(BM I >27) (Ander on et al., 201 3 ). Physica l examination hould aim to identif clinical 
ev idence of athero clero is and r hyperlipidemi a and includ an ocular, cardiova, cular, arotid, 
respirat ry and abdomina l examination ( nder on et a!., 20 13 ). 
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xt, btaining ba elin lab ratory m a ur m nt , uch a DL HDL, triglyc rid , gluco e and 
renal function ( FR) i r c mmended. nee thi data i obtained the P P can calculate the 
patient cardiova cular ri k core via the Framingham ri k c re calculator, which determine the 
patient lev 1 of ri k int three categ ri e I w, intermediate and high ri k for V di ea e 
(http:/lwww.cc .ca/imag I uid eline IT ol and alculat r n/Lipid _ ui_201 2_FR _ ol_ 
EN .pdf#page= l&zoom=aut ,- 1 9,540) . Thi ri k a e m ent h lp to illu trate which patient 
would mo t likely benefit from primary prevention trategie uch a pharmacological treatment 
of hyperten ion and dy lipidemia (Ander n et a!. , 201 3 ). Interval fo r creening are propo ed 
based on Framingham ri sk core, and include ere ning a above every thr e to fi ve year if 
Framingham ri sk score is under 5% and annuall y if core is above 5% (Anderson et al. , 201 3 ). 
Andropause. The finding demonstrate the sympt m of andropau e, uch a hot Oa he , 
night sweats, gynecoma tia, loss of libido and sexual dy function are common, imm diate and 
bothersome side effects to ADT. However, creening recommendations are infrequ entl y 
emphasized in the literature. For example, literature findings fa il ed to present any screening 
recommendation fo r hot fl ashe or night sweats. Moreover, gynecomastia wa briefl y 
mentioned in one of the five clinical practice guidelines, with a focus on earl y a e ment and 
treatment wi th radiation therapy if necessary and de ired (NI E, 20 14 ). This suggests to the 
reader that thi group of ide effect is either entirely known to P P and therefore require littl 
attention in creening recommendation or the e side effect are imply common and as umed 
outcome f trea tment therefore requir littl e focu by P P . urpri ingly, only four of the 
twenty- two paper fro m the li terature review acknowledged andropause ymptom with 
supplemental recommendat ions. f the e fo ur paper , the mo t commonly defined mptom is 
exual dy functi on. lntere tingly, men in frequentl y di clo ed se ual ide eCCccts with P Ps that 
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lik ly c ntribut to th large gr up of men that w re 1 ft untreated for thi ide ef[i ct de pite 
de ire tore ume exual activity ( runfeld tal. , 20 12). !though anticipat d change to exual 
function are m t conunonly related to depl tion of te to teron , it i al o e entia! to anticipate 
chang to libido, exual re p n e and intimate r lati n hip du t impaired percepti n of body 
image, ma culinity and exual attractivene (Harringt n et al. , 2009) . Ba d n the e findin g it 
become evident that P P play an e enti a! rol in en uring pati ent wh de ire exual activity 
and intimacy are creened appr pri ately and pr vided the nece ary treatment option uch as 
pharmacological agent and c un !ling ( nmD ld t a!. , 20 12) . 
As specific ide eU ct and their treatment are expected to occur at pecific point in 
ADT treatment, P P must en ure the appropriat ide effect are being routinely creened. For 
example, treatment with radiation therapy or Tamoxifen may be offered for gynecoma tia which 
occurs within one to three month of treatment initiation, therefore creening for thi condition 
must occur at the first follow up appointment after starting ADT (N ICE, 2014 ). 
Similarly, exual function should be screened regularly in order to identify the i ue a 
early a possible to ensure the appropriate suppot1 and treatment i offered . Thu . . creemng IS 
recomn1ended at regular intervals tlu·oughout treatment, beginning at the first follow up 
appointment after ADT initiation (NCCN, 2015c) . Those with identified i ue hould then 
undergo a more thorough evaluation, which hould include p ychosocial i ue , uch a 
depre ion, impaired body image, relation hip problem , or ther contributing fa ctor uch a 
drugs or alcohol (N N, 20 15a; N N, 2015c) . La tly, a phy ical e amination hould be 
considered in those wi th exual dy function, with a focu on the che t for gynecomasti a, 
abdomen, phallu , cr tum and tc ti le , and the cardiovascular ys tcm (N N, ~0 15c ). 
hi paper recommend the u e of validated tool s to a es, for andropause , ymptom. , 
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uch a the Distre Thermometer (DT) (http: //www.nccn.org/profe ional /physician_gls/pdf 
/senior.pdf) and the exual Inventory for Men ( HIM) (http ://www.auan t.org/education/erectile 
-dy functi n.cfm). Neither tool were included or reco1m11ended in the tudy finding for 
creening, however both have demon trated validity and reliability for creening in cancer 
patients (Cappelleri & Ro en, 2005; , 2015c) . The DT tool i quit inclusive and addre es 
many of the cmmnon ide effect to ADT, including exual dy function. This tool can be 
completed prior to appointment , aving time a P P can simply refer to the identified issue , or 
can be u ed to prompt P P to asses pecific ide effect . More pecific to exual health i the 
SHIM, which i recommended by the (2015c) and ub equently thi paper. Thi hort 
screening tool screens for erectile dysfunction and tho e who may benefit from treatment for this 
condition (NCCN, 20 15c). 
Anemia. The conelation between anemia and both cancer and ADT is well e tablished in 
the literature (Curtis et al., 2008; Dicatol et al., 201 0) . Despite this as ociation, very little 
information was found in the literature with regard to screening or ymptom asses ment. This is 
an important gap as symptoms associated with anemia, such as fatigue and dyspnea (Curti s et al., 
2008), should be a consideration when it comes to symptom assessment and management. 
Nonetheless, screening is only reconunended by two studies via a hemoglobin measurement 
(Curtis et al. , 2008; AU, 20 15). Consequently, ba eline laboratory investigation via a 
hemoglobin or hematology panel should be considered in order to trend hemoglobin va lue with 
the initiation and or long tem1 treatment with ADT. As the literature demon trate anemia an 
occur within three to six month of ADT initiation , therefore repeating r emng v1a a 
hem globin would be appropriate at that time or sooner if clini ally indicated . creening 
interval should depend on clinical presentation and symptom a w II as con ideration of co-
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morbiditie . Co-morbiditie , uch a impaired kidn y function, coagulation disorder , nutritional 
in ufficiencies and inflammatory di ea e hould be con id red a a c ntributing factor to an mia 
and may change interval for creening (Dicatol et al., 20 1 0) . 
Cataracts. Regrettably, re earch finding failed to produce any literature with 
recommendation related to catarac t creening or y xaminati n in general. Thi limitation is 
likely related to cataract being a new defined ide effect to ADT. However, for the sake of 
comprehen ivene , g neral reconunendations derived from the anadian phthalmic Society 
(CO ) are provided to help guide P P in providing care. (2007) recommend regular 
ocular exams in the adult population, with interval depending on risk and age. High risk pati ents 
include those with diabetes, and family history of ocular conditi ons such as cataracts. Although 
ADT is not currently a documented ri sk fac tors id entifi ed by the OS, given the potential for 
increased risk of cataracts with this treatment regimen it is suggested that those receiving ADT 
be considered to be at higher risk and therefore pursue screening more frequently. Therefore, a 
recommended by the COS (2007) , those who are asymptomatic and receiving ADT hould 
undergo screening at least every two years for tho e over the age of 50 and annually fo r those 
over the age of 60. Patients who identify visual changes such as impaired visual acuity, visual 
fields, color visions or physical changes to the eye should be examined as soon as poss ibl e by an 
eye specialist (COS, 2007). 
Bone mineral density impairment. The most consistent recommendation for screening 
in men with prostate cancer receiving ADT appears to be bone mineral density te ting. ll five 
clinical practice guidelines provide some form of rec01nmendation as do the majority of the 
clinical reviews, however th re are incon i tencies noted in initiation of creening, frequency and 
intervals. or the most part, the majority o[ r commendations uniformly propos ba ~ lin e bone 
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mineral den ity cr ning pri r to the initiati n f DT ( u tralian anc r Network, 20 1 0; 
Mohile et al. 2009; Wilkin net al. , 200 ). While interval and frequ ncy f creening ar 
variable, with recommendati n varying from n ugge tion n frequency, to annually, t very 
two year revery 6-24 month re pectively ( u tralian anc r N tw rk, 201 0; M hil e et al., 
2009; ayl ret al. , 2009, Wilkin n et a!., 200 ). What remain c n i tenth wever i the 
ugge ted meth d of a e m nt for bone mineral den ity, with the u e of the World Health 
rganization FRAX tool along ide a D X can . lth ugh mall variation do exi t a orne 
author ugge t FRAX in conjunction with D XA can (Alberta Prov incial enitourinary Tumor 
Team,2013 ; Al- ham ietal. ,2012)whil eother ugge ta tepwiseapproacht cr enmg 
which starts with the le inva ive FRAX and propo e DEXA if ri k i identified by the FRAX 
(NCCN, 2014). 
lntere tingly only one study with a focus on impaired bone mineral density recommended 
a history and physical asses ment for those on ADT in order to identify ri k factor for 
osteoporosis . Although the FRAX a es ment does require data gathering through a focu ed 
history in order to obtain infonnation for osteoporo i ri k, it doe not cover other avenues that 
would suggest risk, such as physical and functional decl ine. A uch, what then become 
glaringly absent in many of the osteoporosi and fracture ri k as e ment recommendation ts an 
as e ment of physical function, uch as mobility, balance and gai t a impairment in the e area 
may increase ones usceptibility for falls and thus fractures . ther tudie h wever, uch a 
Bylaw et a!. (2008) and Mohile et a!. (2009) link alter d phy ical function uch a impaired 
balance and strength with risk for fall and fracture and usc thi ~ information to prcmi e creening 
recommendati n . 
N nethele , the litera ture supports crccning bone mineral density. In ·onsist ~n ·ic , 
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however do not lend for traightforward recommendation , therefore clinical prac tice guid lines 
from 0 teoporosis anada , by Papaioannou et al. (20 l 0) will be propo ed for osteoporosis and 
fracture ri k creening in thi paper. A uch, recommendations will begin with empha i on 
screening all men undergoing DT regardle of age. This should include an initial bone 
mineral density a se ment via a DE 
focu ed history, phy ical exam ination and FRAX a sessment (http ://www .rheumatology.org/I-
Am-A/Rheumatologi t/Re em·ch/ linician-R earchers/Fracture-Ri sk-A sessment-Tool-FRAX) 
(Papaioannou et al. , 20 1 0) . Bone mineral den ity te ting hould be repeated annually while 
undergoing ADT, pa1iicul arly if treatment fo r o teoporosi would be acceptable to the pati ent. 
However, if the pati ent would not consider phannacological treatment fo r osteoporosis one 
should consider the nece sity for bone mineral den ity testing. 
Acute kidney injury. Similar to cataracts, acute kidney injury appears to be a relatively 
newly defined side effect to ADT as there is very littl e data availabl e describing this is ue. The 
studies that are cunently available propose fmi her research to investigate the clinical impOiiance 
of this side effect (La pi et al. , 20 13). Consequently, of the available research studie identifying 
this side effect, screening rec01mnendations are not provided, therefo re thi ide effect wa not 
defined in this paper ' s findings. 
In light of the sugge ted association between ADT and acute injury and the impact 
prostate cancer itself can have on renal fu nction, it is reasonable to screen for kidney function 
periodi call y throughout treatment. Interva ls for creeni ng hould depend on pati ent' s age, 
condition, presence of co-morbiditie and phannacological agents pre cribed. Screening fo r 
kidney function via a creatinine and or glomerular fi ltration rate (G R) hould be added to other 
regular screening laboratory work such a hematology paneL fas ting gluco e or li pid and be 
done at 1 a t annually. r tho 
or have c m rbid conditi n 
mg p cific m dicati n that ar p tentiall y nephrotoxic 
n ri k frenal i ue , creenmg h uld be 
con ider d mor frequ ntly uch a very thr t ix m nth . 
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Cognitive impairment. M hile et al. (2009) acknowledge th impact cognitive 
impaim1ent can hav n cancer pati nt , p tentially nega tiv ly impacting cancer ca r outcome , 
treatment t lerability and pati nt de i i n-making. De pite thi identified va lue in creening and 
potential for identifying underlying c gnitive i ue , very few finding recomm nded uch 
creening. Mohile et al. (2009) and M hi! tal. (20 1 0) both advocate for ere ning for cognitive 
impairment prior to the initiation of ADT in order to identify those with underlying cogniti ve 
defi cits in which treatment may be offered or require further monitoring. Moreover, cognitive 
creening wa particularly empha ized for tho eat higher risk of developing condition uch a 
dementia (Mohile et al., 201 0). Unfortunately, a guide or tool was not provided in the literature 
findings. 
Although study findings present evidence to support screening for cognitive impainnen t 
in some patients with prostate cancer receiving ADT, very lit1l e evidence was available to 
upport initiation, method or intervals of cognitive impai1ment creening. onsequentl y, further 
evidence was sought from the literature in order to provide concrete recommendation . While 
Mohile et al. (2009) and Mohile et al. (20 1 0) recommend all patient be creen d for cognitive 
impairment, current evidence suggest that screening for c gni ti ve i sue in tho e without 
ympt m of impairment in in uffi cient (U. Preventative ervice Ta k For e, 2014 ). 
However, cognitive creening is upported if patient , family or P P identify ign and 
ymptom f impairment (N N, 20 15b; U. Preventative ervi ·e Task Force, ~0 14 ). Tho c 
with identified impaitment should be ere n d for potentially re cr ·iblc or contributing ractors 
to cognitive impairment uch a medicati n , moti nal di turbance , co-morbiditie , ub tanc 
u , and ymptom burd n h uld be done by th P P (N , 20 15b ). Additi nally pecific 
que tioning clarifying the nature f impairment i r c mmended . xampl provided by the 
N N(2015b)includ: 
Table 4 Screen in Question to A, es ognitiv Impairment in anc 7 r Patient 
Do you have diffi culty paying attenti n? 
Do yo u have di fficulty multita king? 
D you fr qu ntly leave ta k inc mpl ete? 
Do you have di fficulty finding word ? 
D you have di fficulty remembering thing ? 
Do you need to use more prompt to remember 
thing ? 
Does it take you longer to think through probl m ? 
Do you notice an impact on functional 
performance? Job performance? 
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If cognitive creening is required due to identified impairments, P Ps should continue to 
monitor signs and ymptom throughou t treatment to monitor for progression and or offer 
appropriate treatment. Finally, a neurological examination may al o be indicated, in which 
additional assessment or imaging may be indicated if focal neurology defect are noted (NCC , 
2015b) . A refeiTal to neuropsychology may also be considered (N N, 20 l 5b) . 
Depression and distress. Based on overa ll prevalence of depression in the general 
cancer population in conjunction with risks associated with ADT it seem practical to creen for 
depre sion in this patient population, however the literature provide littl e recommendation . For 
example, Mohile et a l. (2009) empha ize creening ford pre i nand oth r mental health 
i ue , whi le Pirl et al. (2002) sugge t ' appropriate and regular' a e mcnt or mood. and Lee et 
a!. (20 14) advi e the identification and treatm nt of d press ion hould b a priority. The 
Au tralian anc r Network (20 l 0) provide equally ambi guou, 'Oun I, uggcsting hea lth 
i nal be aware of the ri k fa ctor for an i ty and d pre i nand be pr pared to treat 
appropriately. Method for r ening and to 1 are not ugg t d by any of the finding . 
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In order t upport pati ent with appropriate m ntal health erv ice for di tre the P P 
need to identify th i ue. Ideall y pati nt noti fy their P P f i ue and c ncem or P P ask 
about mental h alth i u regularly, how ver, ti gma and time con traint often tifl e di cu wn 
regarding mental health i ue ( N , 20 15d). v ral tudie have identifi ed low concordance 
rate between pati ent If-report of di tre or mood alterati on with that f phy ician clinica l 
impre ion , which support the u e f tandardi zed validated tool for mea uring p ychol gical 
is ues in tho e with cancer (Litof ky et al. , 2004; ollner, Devries, & teixner, 2001 as cited in 
N CN 2015d). 
What become more complica ted i recommend ations for what pecific tool to use. 
There are a vari ety of systematic reviews and individual research studi es examining the u e of 
the varied validated screening too ls available with very littl e consen u on the ideal tool but an 
overall consensu doe exist for the need and importance of screening (Austra li an Cane r 
Network, 20 1 0; Lee et al. , 20 14; Mobile et al. , 2009; Pirl et al. , 2002) . Therefore, this paper 
recommends the adoption of cunent psychological screening too ls recommended by one cun ent 
facility or as fo llows. 
The NC N (20 15d) guidelines for survivorship, which focu es on the late effects and 
long tenn psychosocial and phy ical problem a ociated wi th cancer and it treatments 
recommend ei ther the PHQ9 or PHQ2 as valida ted as e ment tool for depre ion in the cane r 
survivor population ( doi : I 0. 1 046/j .1525-1497.200 1.016009606 . ). The pati ent hea lth 
que tionnaire (PH ) i a clf-admini ter d diagno tic instrument for criteri a ba ed di agno ' i , of 
menta l health di order such a dcpres ion (Kroenke, pitz r, ' Willi ams, 200 1 ). Th , PHQ9 
con i ts of nin crit ria upon which depre ion i diagn ed ba ed n the D M -IV depr 1ve 
di order (Kro nke et al. , 2001 ). imilarly, th PH 2 c n i t of 2 qu tion to creen for 
depre ion in which if c re are high for depre i n, additi nal qu tion mu t be a ked to 
e tabli h diagno tic criteria (Kroenke et al., 2001) . The b nefit fth e t ol i diagn tic 
validity, with the ability to both diagn e and grade the everity f depre i n (Kroenke et al., 
2001 ). It application to the DT populati n relate t parall el i ue faced by the ADT and 
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urvivor hip p pulati n, uch a d pre ion, b dy image i ue , exual dy fun ction and c gnitive 
impairment. Therefore the e tool may prove helpful when a e ing form d in the pro tate 
cancer populati n receiving ADT. 
TheN N (20 15d) al o recommends using the Di tre Thermometer (DT) and 
accompanying 36 item problem li st as an initial screening tool for cancer related di stress. Thi 
tool identifie the pre ence and level of distress as well a ource uch as practi cal, family, 
emotional, piritual and physical issues related to cancer and its treatments (http ://www.nccn.org 
/professional /physician _gl /pdf/senior. pdf) . Thi validated screening tool was developed 
specifically for cancer patients and ha demon trated good en itivity and specificity, a well as 
good con-elation with other p ychological tool uch as the Ho pi tal nxiety and Depre ion 
scale (N N, 20 15d) . Mitchell, Kaar, Coggan and Herdman (2008) note it wa deemed 
acceptable to 75% of clinicians when used (as cited in NCCN, 2015d) . Although thi tool doe 
not singularly screen for psychological conditions uch a d pres ion, it allows for a broad 
creen for cancer trea tment related effects that can influence psychological health . Moreo r, a 
this to 1 screen for a variety of side effect , it u e may eliminate the need to complete a vari ty 
of scr ening tool for each component f health, su h a phy i al, cognitive and r s ·hological. 
Altered body image and lo s of masculini ty. For a large majority of men r ceiving 
ADT for pro tate cancer, ide ef:fl ct do not occur in i olation . Many of the ab v ide effect 
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can directly or indir ctly impact ther area of health and well -being. For example, DT related 
change to physical appearance uch a gyn c ma tia and exual dy function w re identifi ed to 
significantly impact men' percepti on of ma cui in ity, attrac ti vene and body image ( run feld et 
al. , 201 2 · Hanington et al. , 2009) . More ver, in order to provide patient centered, holistic care, 
P P need to con ider the impact the e changes to body image and ma culinity may have on 
men and their quali ty of life . The literature ha ugg ted a po ible connection between change 
to physical appearance with depres ive symptomology, which may be related to alterations in 
self-e teem and the impact of side effects on intimate relationships (Hanington et al. , 2009; Lee 
et al. , 2014). Therefore, PCP must anticipate changes to psychological health and thus creen 
early and frequently, starting at the first fo llow up appointment in order to support, educate and 
treat appropriately. As identified in study finding , patient and PCPs may be reluctant to openl y 
discuss these issues due to embarrassment or discomfort , therefo re the use of a screening tool, 
such as the Body Image Scale (http ://tools.farmacologiaclinica.info/index .php ), which is pecific 
to body image changes related to cancer, or the DT may be indica ted to identify those with 
altered body image (http ://www.nccn.org/profess ionals/physician_gls/pdf/senior .pdf) 
(Harrington et al. , 2009; N CN, 2015d). 
omprehensive recommendation have been developed to support PCP with creemng 
men with prosta te cancer receiving ADT. Proposed screening recommendations were deve loped 
based on the above re ea rch finding and supplem ntal evidence described in the literature. 
Recommendation included both method and int rval for scr cning a vari ty of physica l, 
cognitive and psychological side effects to ADT. In light of tim on traints noted in primary 
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care, a ne page umn1ary of creening r commendation wa d veloped to provide a quick 
reference for PCP providing care to thi patient population, which i provided below. The final 
component of thi chapter will di cu implication for practice, uch as patient and P P 
education need and fmiher re arch requirements. 
Table 5 Sum.mary of lini al Practi R omm ndation 
Health Domain R commendation 
Impair d -Fun 
phy ical 
function 
Metabolic 
Andropau e 
Anemia 
Cataracts 
Impaired bone 
mineral 
density 
Acute kidney 
ognitive 
impairment 
rna culinity 
- alculate Framingham ri k core. 
-Laboratory creening: LDL, H L, 
tr1 glycerid gluco e and FR 
-Phy ical examination 
-Phy ical exam patient for gynecoma tia 
-Inquire about hot fla he and night 
weat . 
- exual dysfunction creen through 
inquiry or u e of a screening tool uch a 
the DT or HIM. 
-If exual dysfunction , exam phallu , 
scrotum and testicles, and the 
cardiovascular y tern (N N, 20 15b). 
-Laboratory studie to include a 
hematology panel or hemoglobin. 
-General eye examination by an 
ophthalmologist. 
-DEXA scan and fracture risk assessment 
based on a history, physical and FRAX 
assessment tool. 
-Laboratory a e sment (creatinine, 
GFR) . 
-Screen for potentially 
reversib le/contributing factors . ons ider 
neurological examination or re[i nal to 
neurop ychology. 
-PHQ9/PH 2 or the DT 
dy ]mage 
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Int rval 
-Pri r t DT initiation and then 
annually. 
- P every 3-6 month . 
-Ba eJine lab prior to ADT and 
then at lea t annual ly if 
Framingham ri k score >5% 
-Phy ical examination every 3-6 
m nth . 
initiation. 
-H t fla hes, ni ght swea ts and 
exual dy function should be 
a e ed at first follow up 
appointment after DT initiation 
(within 3 months) and then 
every 3-6 month ). 
-Prior to ADT, repeat within 3-6 
month , then at least annually. 
- very 2 years >50 and annuall y 
for tho e >60 years old . 
-Ba eline D XA/FRAX and 
repea t annuall y. 
-A se s if patients, family or 
P P identify sign and 
ymptom of impairment. 
- very 3-6 months . 
- , s within 3 month 
mitiation and repeat C\'Cr 
months. 
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Recommendation for Education 
Finding have al demon trated gap in b th pati nt and P P know! dg and education 
regarding ide efD ct and ere ning requir ment ~ r DT, b th f which impact ca re. r 
xampl , evera l tudie have d m n trated that awarene of conllTion DT ide ef~ ct varied 
ignificantly am ng t patient , a m patient attribut d ef:D ct to e ither age or unknown 
cau e or de cribed urpri when ympt m ar e ( runfeld et al., 20 12; M hi le et al., 201 0) . 
Furthermore, de pite guideline and in.G nnation regarding p cifi c adver e effect , uch a bone 
lo sand ADT, overall kn wl dge, percepti n f u ceptibility and engagement in preventative 
behaviour wa demon trated to be low v rail (Nadler eta!. , 2013 ). In addition to gap m 
patient education identified in th literature, it i al o noted that pati ent are frequentl y 
dissati sfied with the education they received fr m health care provid ers (Chapman & Ru h, 2003 
as cited in In titute of Medicine, 2008). Based on the e finding it i evident that patients would 
benefit from an open di cu sion with specific and clear evidence ba ed education regarding ADT 
and its side effect (Nadler et al., 2013) . Further, through providing thi education pati ents will 
better understand reasoning for creening which may influence uptake. 
Screening it elf provides an important opportunity as it may lead to pati nt eeking 
further knowledge regarding side effects and provides an entry point for di cu ion and 
education from P Ps (Nadler et al. , 20 13 ). In order to increa e the uptake of infonnation, two 
things should be considered. Fir t, adequately managing ide ffect to illne , uch a an iety or 
pain may be u eful with comprehension and sati sfac ti on wi th information pro ided ( hapman & 
Ru h, 2003 as c ited in In titute of Medicin , 200 ). econd ly, information should b tailored to 
each individual, ba -d on education, clini al ituation, diagnosi , e p tation and preferences 
(In titute of Medici n , 2008). ore am pl , me prefer very detailed information while others 
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pre£ r 1 detai l but pr fer infi nnation be pr vided nan a needed ba i (In titute of M dicine 
200 ). Finally, in£ nnati n need chang thr ugh the di ea traj ct ry, therefore inf01mation 
hould be offer d regularly (In titut f M edicine, 200 ). 
imilarly, P P' al or quir m r educati on r ga rdin g creening requir ment forth 
receiving DT for pro tate cane r. Thi demon trated by th p or uptake of creening for 
commonly defined ide effect to DT uch a impaired b ne mineral density a well as pati nt 
uncertainty of ide effect ( 1- ham i et al. , 20 12; hapman & Ru h, 200 a c ited in In titute 
of Medicine, 200 ) . Poor uptake in creening prac ti ce and pati ent edu cati n i likely 
multifaceted , including limited clinica l practi ce guide lines, P P uncertainty about current 
practice and guidelines, a lack of edu cation r garding the u efuln s and application of creening 
tools , and an overall lack of education of the impact of ide effect and th ir con equence on 
overall health and well-being (Al- hamsi et al. , 20 12). Thus, it tand to rea on that the 
development and di tribution of comprehensive guidelines would prov ide P P with the support 
and education required to provide appropriate care for those with prostate cancer receiving ADT. 
Consequently, consolidating current evidence and pur uing gaps in re earch to develop one 
comprehensive document should remain a focus for researchers and profe ional organiza tion . 
Consequ ently, education, further research and guideline development is r quired . 
ducation must be targeted to those prescribing and managing the care of tho eon DT, uch a 
P Ps in order to increa e screening and reduce DT as ocia ted morbidity ( libhai et a!., 20 12) . 
Ideally, thi education would be in the form of comprehensive guideline~ , however in the interim 
regular educa ti n session and appropriate di emination of information that focu es on current 
evidence and clinical practi ce guidelines related t reening ma y be u 'eful (Tomasone et al., 
20 15). AI- hamsi eta!. (20 12) noted some , u ce with profc s ional group workshops in 
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increa ing P P knowl dge of cr ening foro t p r i and the id ntifica ti n of ri k factor in a 
2008 tudy, and ugge t imp! m ntati on f imi lar ducati n initi ati e for P and NP . h 
goal of the e initiative w uld b t increa e P P ' kn wl dge regardin g ide ef[i cl f ADT, 
the benefit and recommendati n fi r creening, and the importance of di minating thi 
informati n t pati nt . Mor over, enc uraging c ordinat d and harcd care betw en P P and 
oncologi t hould be con id er d, a thi w uld all w fi r P P t u e the oncologi t a a 
upportive re ource and con ult a needed with regard to T creening recomm ndati n or 
ide effect management ( '20 15b). 
Recommendation for Research 
Finally, a aylor t al. (2009) indicate ome of the DT related side effects are newly 
identified and therefore not fully defined . Thi sugge l fu rther research into the ide effects of 
ADT in order to adequately develop evidence ba ed creen in g recommendati on and guideline . 
Moreover, it may be beneficial to focus research on the younger prosta te cancer popul ati on as 
this may potentially identi fy new theme or hi ghlight side effects that may be more likely to 
occur or cause distress compared to men in an older coh011. imilar i ue were validated in 
previous brea t cancer studi es which demonstrated ignificantly more di tress regarding body 
perception in younger populations (Han ington et al. , 2009) . Such findings will allow for greater 
support to this patient popul ation. 
onclu ion 
Th r arch que ti n , for P pra ti ing in a ptimary care tting, what ere ning i 
required to identify ide effi ct in m n with pr tate cancer r c iving DT wa xpl red in thi 
literature revi w. In order t an wer thi que ti n th literature wa earch through a variety of 
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uch a the chrane library, HL, Pubmed and Joanna Brigg In titute Library 
a well a th grey literature. Thr ugh vati u c mbinati n f arch term and the application 
of inclu ion and exclu ion criteria , a t tal of 22 article were elected that were pertinent to the 
re earch que ti n. 
There earch finding demon trated few clinical practi ce guideline that pre ent 
recommendation for creening for DT related ide effect . M reover, the guid eline that are 
available lack con i tent and comprehen ive recommendations for creening. on equentl y, 
without guidelines to upport primary care practice and aid deci ion making, P P do not have 
the mean to adequately support thi patient population. A vari ety of other is ues has pre ented 
baiTiers to PCPs screening patients appropriately, such as a lack of knowledge, time con traints 
and provider di scomfort addre ing specific adverse effect . Pati ents too have demonstrated a 
lack of awareness of ADT side effects which may limit their probability to report ide effect to 
their P P . Finally, although there is an abundanc of literature regarding ide effect to ADT, 
new adverse effects are being identifi ed in the literature, ca lling fi r further re earch into pecific 
risks of treatment. 
Through an integrative review of the literature, current recomm ndation , method and 
interval of creening were reviewed . Recommendation for practic ha e been pre, en ted based 
n a con olidation of the e finding in conjun tion with other evidcnc ba ed guidelines . 
pecific recommendati n include regular clinical follow up, tat1ing within three months of 
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tr atm nt initiation follow ed by a revi w ev ry three to ix m nth . During each£ 11 w up 
appointment, pati nt may b f£ r d a variety f va lid at d ere ning t r imply und rg 
inquiry of ide effect fr m th ir P P m rd r to identi fy adver e effect to DT and provide 
the appropriate upp rt and treatment. llow up app intment mu t al o include a phy ical 
a e ment a w 11 a intennittent lab ratory tudi e which w re identified in detail ba ed on 
individual ide effe t f DT. In any vent, pati ent are t be creened for phy ical, cogniti ve 
and p ychological is ue prior t initiating treatm nt and thr ughout the treatment r gim en. 
Additi onall y, pati ent and P P' require furth er educati n rega rdin g A DT ide effect and the ir 
potenti al impact on ov rall health and well -be in g, whil e P P ' mu t n ure they engage in 
appropriate knowledg translati on and regu lar cr ening. Finally, fu t1her re earch i required to 
fu lly define the adverse effect of ADT in order to incorporate evidence ba ed recommend ati on 
and develop comprehensive guid elines. 
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Clin ical Oncology, 30( 15), 1 64-1 70. doi: 10.1200/ J .20 11 .3 .3 745 
Medication 
Luteinizing hormone 
relea ing honn ne agoni t 
• Leuprolide 
• Goserelin 
• Bu erelin 
GnRH antagonists 
• Degarelix 
Anti-androgens 
• Flutamide 
• BicaJutamide 
• Ni lutamide 
Appendix A 
Pharmacological ADT 
Mechani m f 
Action 
The e m dications 
timulate the rel ea e 
of lut inizing 
hom1one causing an 
initial 1 vation in 
erum androgen . 
Chronic 
admini trati n 
causes a reduction in 
the secretion of 
Indicati n 
Indicated for 
localized, 
locally 
advanced 
di a e, 
bi chemically 
recurrent 
disease 
(increasing 
P A) and 
luteinizing hormone metastatic 
and androgens prostate cancer 
through down 
regulation of LHRH 
receptors. 
Competitively binds 
to the GnRH 
receptors in the 
pituitary, which 
reduces the release 
of follicle 
stimulating honnone 
and luteinizing 
honnone which 
reduces the release 
of testosterone. 
Binds to androgen 
receptors, inhibiting 
the binding of 
testosterone and 
dihydrate to terone. 
Used in 
metastatic 
prostate cancer, 
as an alten1a ti ve 
to GnRH 
agonists . 
Can be used as 
first lin 
mono therapy 
for advanced 
prostat can er, 
in combination 
with GnRH 
agonist for 
advan ed 
prostate cancer 
Ad1nini tration and 
Dosage 
Leuprolide: 
97 
1 month d pot 7.5 mg 
IM, 3 month depot 
22.5 mg IM or 4 
month depot 30 mg 
IMOR 
3 month depot 22.5 
mg SC or 6 month 
depot 45 mg 
Goserelin : 
3.6 mg SC monthly or 
10.8 mg SC ev ry 3 
months. 
Busere1in: 
6.3 mg SC every 8 
weeks or 9.45 mg C 
every 12 weeks . 
Two 120 mg 
injections (240 mg 
total) SC on day 1 
followed by 80 mg SC 
monthly. 
Flutamide: 
250 mg PO thre 
time daily 
Bicalutamide: 50 mg 
PO once daily 
ilutamidc: 
00 mg P once dail 
for 30 days or less, 
YP17 inhibit r 
• 
• 
Ketoconazo l 
Abirateron 
in the adrenal gland 
re ult in a reducti n 
in the production of 
androgen . 
or a econd 
lin therapy 
after 
pr gre 1 n n 
nRH agoni t 
pr tate cancer 
after 
chem therapy 
trea tment 
failure . 
then 150 mg P 
daily. 
Ketoconazo le 
Abiraterone: 
1 gram once daily P 
(B A, 20 12a; B A, 20 12b; B A, 20 12c; B A, 20 13; Perlmutter & Lcpor, 2007) . 
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ppendix B 
Literatur arch Fl w ha1i 
Potentially relevant paper identified by 
database searching (n =1198) 
Addit ional records identified through 
other sources (grey literature, hand 
searching) (n =140) 
Paper for review (after duplicates removed) 
(n =1338) 
Titles screened 
(n =1338) 
Full -text articles assessed for 
eligibility 
lr 
(n =SO) ~ 
+ 
Additional articles selected 
from references of full text 
articles (n =3 ), but ultimately 
excluded due to exclusion 
criteria 
Total papers mcluded in the 
review 
(n =22 ) 
Records excluded after 
review of title/abstract 
(n =1288) 
Full-text articles excluded, 
with reasons 
(n =2 8) 
-Main reason for exclusion 
was lack of screening 
recommendations 
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